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EPIDEMIOLOGY
Ovarian cancer is the second most common gynecologic malignancy with an incidence 
of about 15 cases per 100,000 women in Western countries [1-3] and is ranked the 
seventh leading cause of cancer-related death in women worldwide [4,5]. The high 
mortality rate is due partly to the fact that most ovarian cancers are diagnosed at an 
advanced stage of the disease. Early ovarian cancer accounts for approximately one-
third of all newly diagnosed ovarian carcinomas [6]. The early-stage disease is defined 
by the International Federation of Gynecology and Obstetrics (FIGO) as stage I and IIa 
and is histologically confined to the internal gonads in the small pelvis [7]. Worldwide 
around 68,000 new cases of early ovarian carcinoma will be diagnosed annually [5]. 
The cumulative risk (age 0-64) for ovarian cancer is 0.5 [5]. The incidence of early-stage 
ovarian cancer in the Netherlands is approximately 370 patients per year. The median 
age at diagnosis is 57 year with around 30% less than 50 year [8].
CLASSIFICATION
Patients with ovarian cancer are surgically staged according to the FIGO classification.
In 1964 the general assembly of the FIGO approved on a stage grouping of ovarian 
carcinoma [9]. Hereafter investigation of large series of ovarian cancer led to a definitive 
stage defining by the Cancer Committee of FIGO in 1971 [10]. General agreement 
existed on the importance of the penetration of the ovarian capsule by the tumor in 
stage I ovarian cancer, but opinions differed as to whether the presence of ascites had 
an influence on the outcome [11]. Ascites which had to contain malignant cells was 
only incorporated in stage Ic. Capsule rupture has been shown a prognostic indicator 
for disease-free survival in some studies [12-13]. In 1975 further refinements came when 
final histology after surgery was to be considered in the staging and Ic was no longer 
subdivided according to the rupture of the ovarian capsule and grouped together with 
those cases in which ascites was present, not necessarily containing malignant cells, or 
positive peritoneal washings [14]. In 1985 the FIGO modified the staging for ovarian 
carcinoma in part to reflect the prognostic significance of metastatic spread to the pelvic 
or para-aortic lymph nodes. In disease confined to one or both ovaries, positive nodes 
result in an upstaging to stage IIIc [7]. The latest revision of the FIGO classification was 
in 2009, but no modification for the staging system of ovarian carcinomas was made 
[15,16].
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PATHOGENESIS AND HISTOPATHOLOGY
Several theories exist on the pathogenesis of epithelial ovarian cancer. While it is widely 
believed that the epithelial component of the ovary gives rise to the common epithelial 
ovarian carcinomas [17], it is not clear whether these cancers originate from a single-
cell layer of surface epithelium or in architectural aberrations of the surface epithelium. 
These include surface epithelial-lined clefts and cortical inclusions cysts, thought to 
result from post-ovulatory wound repair, tissue remodeling associated with pregnancy 
or aging, para-ovarian adhesions, or simply the dynamic interaction between surface 
epithelium and underlying stroma [18-20]. A study of Pothuri et al. supports a model 
in which ovarian cancers frequently arise within epithelial inclusion cysts, but not the 
surface epithelium per se, and that carcinoma may be preceded by a dysplastic precursor 
lesion [21]. Another histopathology-based theory holds that epithelial ovarian cancer 
may arise in components of the secondary Müllerian system, located within or adjacent 
to the ovary [22]. The histologic subtypes of epithelial ovarian cancer include serous, 
mucinous, endometrioid, clear cell, mixed type and undifferentiated tumors. A new 
model for the pathogenesis of ovarian cancer is proposed by Kurman and coworkers 
[23]. In this model ovarian tumors are divided into two broad groups designated Type I 
and Type II. Type I tumors are slow growing, generally confined to the ovary at diagnosis 
and develop from well esthablised precursor lesions (borderline tumors). Type I tumors 
included low-grade micropapillary serous carcinoma, mucinous, endometrioid and clear 
cell carcinoma. They are genetically stable tumors and are characterized by mutations 
in a number of different genes including KRAS, BRAF, PTEN, and beta-catenin. Type II 
tumors, like the high grade serous carcinomas, are rapidly growing, highly aggressive 
neoplasms for which well defined precursor lesions have not yet been described. This 
group of tumors have a high level of instability and are characterized by mutation of 
TP53. Some other studies suggested that type II ovarian carcinomas are perhaps not 
ovarian cancers at all, but rather originate in the fallopian tube [24,25]. 
Different grading systems are used for ovarian cancer. The FIGO grading system 
is primarily based on architectural features, and the grade depends on the ratio of 
glandular or papillary structures versus solid tumor growth within an individual tumor 
[26]. The World Health Organisation (WHO) grading system is dependent on observer’s 
impressions derived from both architectural and nuclear features but not defined in a 
quantitative manner [27]. The Gynecologic Oncology Group (GOG) grading system 
considers architectural and, to a lesser extent, nuclear features, but varies depending 
on the histologic type of the tumor being graded [28]. Clear cell carcinoma of the 
ovary cannot be graded by either the FIGO and GOG grading system. Thus, the grade 
assigned to a particular tumor is dependent on the observer’s diagnosis of the histologic 
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type of tumor, which has been shown to be poorly reproducible between pathologists 
in several studies [29-31].
Silverberg proposed a new grading system modeled on the Nottingham system of breast 
cancer grading and designed to be applied to all invasive epithelial carcinomas of the 
ovary, including clear cell tumors [32].
SURGICAL STAGING
Major advances in the understanding of the natural history of early ovarian cancer 
occurred in the 1970s and 1980s when some authors defined the incidence of occult 
disease in the omentum, paracolic gutters, diaphragm, in the peritoneal washings and 
the lymph nodes [33-36].
Piver et al. report that microscopic metastases in the abdominal cavity at different sites 
like the right diaphragm (11%), the omentum (3%) and malignant cells in peritoneal 
washings (33%) were found in patients with presumed early-stage ovarian cancer [33]. 
Another route of metastasis is via the lymphatic channels. In 1974 Knapp and Friedmann 
reported at first their experience with aortic lymph node metastases in patients with 
early ovarian cancer [37]. In the decades thereafter other studies have extended our 
knowledge about the routes and incidence of lymphatic spread to the pelvic and aortic 
lymph nodes. The anatomy of ovarian lymph drainage is complex. It has been stated 
that the drainage trunks leaving the subovarian plexus take a cephaled course toward 
the aortic nodes via the infundibulopelvic ligament [38]. Another lymphatic channel 
courses from the hilus of the ovary within the folds of the broad ligament to drain 
into the obturator, external, and common iliac nodes which are interconnected by a 
great variety of anastomoses [39]. Lymphatic vessels also enter and travel along the 
round ligament to reach the inguinal region [40]. Involvement of pelvic nodes has been 
reported to occur in 8-15% [33,41] and of para-aortic nodes in 5-24% of patients with 
stage I disease [41,42].
Peritoneal seeding is the most common pathway for the spread of ovarian cancer 
whereby tumor cells slough off the ovary and enter the peritoneal circulation to 
seed multiple sites like the diaphragm, omentum, paracolic gutters, cul-de-sac and 
paravesical recesses [43-45]. Peritoneal fluid is able to flow upward from the pelvis due 
to pressure gradients in the abdominal cavity [44].
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These findings have led to a better understanding of the spread of early ovarian cancer 
within the peritoneal cavity and the need for a comprehensive surgical staging of these 
patients. Complete surgical staging consists of abdominal hysterectomy with bilateral 
salpingo-oophorectomy, infracolic omentectomy, sampling of pelvic and para-aortic 
lymph nodes, careful inspection of the whole abdominal cavity, taking of blind peritoneal 
biopsies and biopsies of any suspect lesions and of adhesions adjacent to the tumor 
and peritoneal washings. The stage of ovarian cancer is defined as the extent of the 
disease at the time of diagnosis. This can only be determined by exploratory surgery and 
meticulous evaluation of all areas of disease dissemination. The surgical procedures 
and the requirements for optimal intraperitoneal surgical staging of cancers apparently 
confined to the pelvis are well established by the FIGO [46]. Different guidelines for 
surgical staging of ovarian cancer were defined like the European guidelines of staging 
of ovarian cancer (EGSOG), the European Organisation for Research and Treatment of 
Cancer (EORTC) guidelines and the Gynecologic Oncology Group (GOG) guidelines 
[47,48]. EGSOG guidelines require lymph node sampling among the external and 
common iliac vessels and along the aorta and vena cava, specifically between the inferior 
mesenteric artery and the level of the left renal vein. The GOG guidelines recommend 
also excision of the distal half of the obturator fatpad anterior to the obturator nerve 
and prescribe dissection from the area between the inferior mesenteric artery and the 
left renal vein only in case of palpably suspicious nodes [47] .
In a study of Petru et al., 55% of lymph node metastases in presumed early-stage ovarian 
cancer were less than 2 mm in diameter [49]. Similar findings have been found by Wu 
et al., 33% of clinically nonsuspicious nodes harbored metastases of epithelial ovarian 
cancer [36].
The result of surgical staging in ovarian cancer is a redistribution of stages. Several 
studies have shown that a substantial number of patients initially believed to have 
disease confined to the ovaries will be upstaged. Young et al. [34] reported on a group 
of 100 patients of whom 62 agreed to be restaged after being referred for treatment of 
stage I or II ovarian cancer. Of these patients almost one third (31%) were upstaged, 
with the final stage in most becoming stage III. Comparable studies by Soper, Hellewa 
and Buchsbaum reported similar results [50-52].
Therefore, the importance of complete surgical staging cannot be overstated. Mc 
Gowan et al. [53] examined the completeness of staging in 291 patients with ovarian 
cancer. Forty six percent of patients were inadequately staged. Proper staging was 
highly correlated with the level of experience of the surgeon who treated the patient. 
Gynecologic oncologists adequately staged 97% of patients, general gynecologists 52% 
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and general surgeons 32%. These findings are also supported by others [53-56]. Five-
year survival and disease-free survival, respectively, for stage I-II ovarian cancer patients 
surgically staged by a gynecologic oncologist were 83% ± 7% and 76% ± 8%, compared 
to 59% ± 11% (P < 0.05) and 39% ± 11% (P < 0.03) for the group operated upon by 
a non -oncologist [57]. In a study of Vernooij et al. among patients with FIGO stage 
I-IIa disease, risk of ovarian cancer-specific mortality was 30% and 42% lower after 
treatment in semi-specialized and specialized hospitals, respectively, as compared to 
general hospitals [58]. In another study the level of specialization and the volume of 
hospitals and the number of gynecologists were strongly related to the proportion 
of adequately staged patients [59]. Comprehensive surgical staging is essential for 
prognostic determination and treatment planning for patients with apparent early-
stage ovarian cancer as it defines a subset of patients that do not require adjuvant 
treatment in order to reduce the risks of late complications of chemotherapy as well as 
the morbidity and costs caused by such therapy [60].
TREATMENT MODALITIES
In the past many randomized trials have enrolled patients with early ovarian cancer 
in order to evaluate the value of adjuvant therapies like external radiotherapy, 
intraperitoneal installation of radionuclides such as gold-198 (198Au) or phosphorus-32 
(32P), single alkylating agents or platinum-based single or combination chemotherapy.
Some of these studies were of low quality because of the omission of a control arm, 
inclusion of borderline tumors and incomplete surgical staging [61-67]. It was stated 
that: “the inclusion of inaccurately staged, incompletely evaluated patients in trials 
attempting to test the potential value, if any, of adjuvant treatment will be difficult to 
interpret at best and misleading at worst” [68].
Meta-analyses performed by Winter-Roach et al. [69] for those trials with complete 
surgical staging procedures comparing adjuvant chemotherapy (AC) versus radiotherapy 
showed no significant difference between the effects of AC and radiotherapy on overall 
survival (OS) and disease-free survival (DFS). The main analysis of OS showed an HR 
of 0.85 (95% CI 0.62 to 1.17) and the DFS showed an HR of 0.94 with a 95% CI of 
0.56 to 1.59. In the subgroups, AC versus 32P, AC versus whole abdominal radiation 
(WAR) or platinum-based AC versus 32P, radiotherapy showed no statistical advantage 
for any modality. Cisplatin containing regimens are preferable to radiotherapy and 
intraperitoneal 32P because of lower toxicity and relative ease of administration.
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Most randomized trials compared two or three different treatment arms and almost 
all had a very low power because of the small number of patients or too few events. 
Furthermore, the efficacy of AC cannot be firmly established without an untreated 
observation arm.
In a study of Young et al. [70], 81 patients with grade 1 or 2 stage Ia or Ib (FIGO 1973) 
ovarian cancer were randomly assigned to receive 12 cycles of orally administered 
adjuvant melphalan and 81 no adjuvant treatment. No significant difference in overall 
survival (OS, 94% versus 98%) or disease-free survival (DFS, 91% versus 98%) was found.
Bolis et al. [71] showed in 85 FIGO stage Ia or Ib, grade 2 or 3 patients a significant 
DFS advantage in the cisplatin group (83%) compared to the observation arm (65%). 
However, when the controls were treated with cisplatin at relapse, they had the same 
overall 5-year survival as the group receiving cisplatin treatment, as an adjuvant modality 
following initial surgery: 82% and 88% respectively. This result suggests that eight of 
the ten women in the cisplatin arm had been overtreated. If survival after relapse is 
compared, the patients in the upfront cisplatin group did much worse than patients 
in the nontreated group. Therefore the authors suggested that salvage treatment was 
more effective in the observation arm than in the chemotherapy arm, but also in this 
trial the number of patients was too small to draw too strong conclusions. 
The Nordic Cooperative Ovarian Cancer Group performed a randomized study between 
1992-1997 in patients with high risk epithelial ovarian cancer (stage I) including 162 
eligible patients comparing carboplatin and observation [72]. High risk was defined as 
grade 2 or 3 tumor, all clear cell and DNA aneuploid tumors, independent of grade. 
Only 10% of the patients had a complete comprehensive surgical staging. The study 
was closed prematurely due to poor accrual. The estimated 5-year OS and DFS rates 
were 86% versus 85% and 70% versus 71% for the adjuvant chemotherapy and control 
group, respectively. 
In a randomized phase III Gynecologic Oncology Group study in early-stage ovarian 
carcinoma comparing 3 versus 6 cycles of adjuvant carboplatin and paclitaxel, the 
latter did not significantly alter the recurrence rate in high risk early ovarian cancer, 
but was associated with more toxicity. There was documentation of complete surgical 
staging of only 71% of patients in this trial [73].
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PROGNOSIS
The survival rates reported in the literature for patients with early ovarian cancer (EOC) 
vary, partly due to the differences in completeness of surgical staging and grade of 
differentiation and inclusion in some series of borderline tumors. The 5-year survival 
rates range from 76-95% for stage I [4,75-78] and 42-70% for stage II patients [75,78].
Over the past decades the improvement of the relative survival has occurred during the 
period in which adjuvant chemotherapy has been used in the treatment of EOC together 
with an improvement of the surgical staging in the same period. Although the overall 
survival curves are good compared to patients with advanced disease, approximately 
10-50% of women with early EOC will experience a recurrence or die as a result of the 
disease [6,76,79,80]. Because of these long-term figures, major efforts have been made 
to develop adjuvant therapies, to optimize surgical staging and to identify prognostic 
factors that can predict patient outcome.
Women with early-stage ovarian cancer have a much better chance of achieving a cure 
than do women with late-stage disease. This difference makes screening for ovarian 
cancer, with the hope of detecting it in its presymptomatic state, an attractive concept. 
Unfortunately, efforts to demonstrate that screening for ovarian cancer in the general 
population can decrease mortality have been disappointing [81]. No accurate screening 
test is available but transvaginal sonography and CA 125 determinations can be 
valuable in selected patients [82] as well as the Risk of Malignancy Index (RMI) [83,84]. 
The results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer 
Screening (UKCTOCS) shows that the sensitivity of the multimodel screening (MMS) 
with annual CA 125 screening with transvaginal ultrasound scan as a second line test 
and annual screening with transvaginal ultrasound (USS) is encouraging. Specificity 
was higher in the MMS group than in the USS group, resulting in lower rates of repeat 
testing and surgery. The results of ongoing screening are awaited so that the effect of 
screening on mortality can be determined [85].
The detection of serum proteomic patterns or other biomarker panels holds promise of 
novel screening strategies and individual target therapies [86-88].
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PROGNOSTIC FACTORS
Prognostic variables can divide patients into risk groups. It is generally accepted that 
stage Ia grade 1 tumors with complete surgical staging have a very good prognosis with 
a 5-year overall survival of 95% permitting fertility sparing surgery [6]. Trimbos et al. 
described a 100% disease-free 5-year survival in patients with well differentiated early 
ovarian cancer who had undergone a careful staging procedure [89]. Young found a 
98% disease-free survival rate in 38 patients with well-staged, low risk early ovarian 
cancer [68]. In a study of  Vergote et al. none of the 77 patients with well differentiated 
DNA diploid tumors had relapses [74].
Several prognostic factors for early-stage ovarian carcinoma have been analyzed. Some 
of them are biological and clinical in nature, but others such as the thoroughness of 
the staging procedure, the extent of the surgery, and the philosophy of treatment, are 
defined by human nature [90].
Many clinical and pathological characteristics have been found to correlate with survival 
in early ovarian carcinoma including stage, histologic type, tumor grade, ascites, age 
and ploidy [15,70,72,89,91-101]. Furthermore rupture of the tumor, dense adhesions 
and surgical staging have been indicated as independent prognostic factors in prior 
reports [89-91,102-105]. In a multivariate analysis of 351 patients with stage I ovarian 
cancer Zanetta et al. [90] found that the extent of surgical staging was a statistically 
significant independent prognostic factor for disease-free and overall survival.
The largest retrospective multivariate analysis in stage I epithelial ovarian cancer of 
Vergote et al. including 1,545 patients, concluded that the most important independent 
prognostic factors were degree of differentiation followed by rupture before surgery, 
FIGO substage Ib versus Ia and age [104].
Also highly reproducible quantitative pathological features which are easy to assess 
have shown to be of prognostic value in early ovarian cancer in combination with 
clinical characteristics. In a study of Brugghe et al. [106] MNA (volume percentage of 
epithelium, mitotic activity index, mean) and MNV (volume-weighted mean nuclear 
volume) were the strongest single prognostic factors for overall survival in a group 
of 102 adequately staged FIGO stage I ovarian cancer patients who did not receive 
adjuvant treatment.
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SCOPE AND OUTLINE OF THE THESIS
In order to evaluate the effect of adjuvant chemotherapy and surgical staging in early 
ovarian cancer patients, the European Organisation for Research and Treatment of 
Cancer - Gynecologic Cancer Group (EORTC-GCG) performed the Adjuvant Chemo-
Therapy in Ovarian Neoplasm (ACTION) trial (EORTC trial 55904). The ACTION trial 
was a randomized study on the role of platinum containing adjuvant chemotherapy in 
early ovarian cancer patients with FIGO stages Ia and Ib (grade II-III) and stages Ic and 
IIa (grade I-III) and all stages Ia-IIa clear cell carcinoma after surgery. Randomization 
between platinum containing chemotherapy and no adjuvant treatment took place after 
surgical staging and patients randomized to receive platinum based chemotherapy were 
treated within four weeks after surgical treatment for at least four consecutive courses.
Because there still exist a lot of discussion and questions about the treatment and 
prognosis of patients with early ovarian cancer, we further examined the surgical staging 
categories and the different subgroups in order to get some answers on these subjects.
In chapter 2 the results of the first analysis of the ACTION trial are described between 
the adjuvant chemotherapy arm and the no treatment arm (observation arm) on the 
role of platinum-based chemotherapy on disease-free survival (DFS) and overall survival 
(OS). Furthermore, analyses were performed in optimally staged patients versus non-
optimally staged patients.
A review of the treatment modalities and recent findings in early ovarian cancer patients 
is given in chapter 3.
The clinical characteristics and response to platinum-based chemotherapy in patients 
with clear cell carcinoma (CCC) versus serous adenocarcinoma (SAC) randomized in 
the ACTION trial are described in chapter 4. 
Early ovarian cancer patients are often incompletely staged during their initial surgery. 
In chapter 5 we discuss the possible reasons for inadequately staging early ovarian cancer 
patients.
The effect of lymph node sampling and taking of blind biopsies as part of the surgical 
staging procedure for early ovarian cancer on DFS and OS in patients who received no 
adjuvant chemotherapy are analysed in chapter 6.
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ABSTRACT
Background: All randomized trials of adjuvant chemotherapy for early-stage ovarian 
cancer have lacked the statistical power to show a difference in the effect on survival 
between adjuvant chemotherapy and no adjuvant chemotherapy.
They have also not taken into account the adequacy of surgical staging. We performed 
a prospective unblinded, randomized phase III trial to test the efficacy of adjuvant
chemotherapy in patients with early-stage ovarian cancer, with emphasis on the extent 
of surgical staging. 
Methods: Between November 1990 and January 2000, 448 patients from 40 centers 
in nine European countries were randomly assigned to either adjuvant platinum-based 
chemotherapy (n = 224) or observation (n = 224) following surgery. Endpoints were 
overall survival and recurrence-free survival, and the analysis was on an intention-to-
treat basis. The Kaplan–Meier method was used to perform time-to-event analysis, and 
the log-rank test was used to compare differences between treatment arms. Statistical 
tests were two sided.
Results: After a median follow-up of 5.5 years, the difference in overall survival between 
the two trial arms was not statistically significant (hazard ratio [HR] = 0.69, 95% 
confidence interval [CI] = 0.44 to 1.08; P = 0.10).
Recurrence-free survival, however, was statistically significantly improved in the adjuvant 
chemotherapy arm (HR = 0.63, 95% CI = 0.43 to 0.92; P = 0.02). Approximately one-
third of patients (n = 151) had been optimally staged and two-thirds (n = 297) had 
not. Among patients in the observation arm, optimal staging was associated with a 
statistically significant improvement in overall and recurrence-free survival (HR = 2.31 
[95% CI = 1.08 to 4.96]; P = 0.03 and HR = 1.82 [95% CI = 1.02 to 3.24] P = 0.04, 
respectively).
No such association was observed in the chemotherapy arm. In the non-optimally 
staged patients, adjuvant chemotherapy was associated with statistically significant 
improvements in overall and recurrence-free survival (HR = 1.75 [95% CI = 1.04 to 
2.95]; P = 0.03 and HR = 1.78 [95% CI = 1.15 to 2.77]; P = 0.009, respectively). In the 
optimally staged patients, no benefit of adjuvant chemotherapy was seen.
Conclusions: Adjuvant chemotherapy was associated with statistically significantly 
improved recurrence-free survival in patients with early-stage ovarian cancer. The 
benefit of adjuvant chemotherapy appeared to be limited to patients with non-optimal 
staging, i.e., patients with more risk of unappreciated residual disease.
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INTRODUCTION
Ovarian cancer is a common gynecologic malignancy. Approximately 30% of patients 
with ovarian cancer are diagnosed with early-stage disease, which is localized to the 
gynecologic organs and has not spread to adjacent structures in the pelvis or the upper 
abdomen. Nevertheless, 10%–50% of patients who receive surgery for treatment of 
early-stage ovarian cancer have a recurrence, and these recurrences are often resistant 
to various forms of salvage treatment [1].
This high recurrence rate has led to attempts to use different forms of adjuvant 
treatment, but solid scientific proof of the clinical effectiveness of adjuvant treatment 
is lacking. Not only is the clinical significance of adjuvant treatment unclear, but the 
definition of which patients are at high risk of recurrence—that is, in potential need of 
adjuvant treatment—has remained obscure.
Few randomized trials have tried to address the uncertainties that have been created 
by this ‘act-before-proof’ approach. Young et al. [2] reported a Gynecologic Oncology 
Group (GOG) study in which patients with stage Ia or Ib and grade I or II ovarian cancer 
were randomly assigned to either observation or intermittent oral melphalan following 
surgery. There was no survival difference between the two groups of patients. Although 
the number of patients in this trial was too small to draw definitive conclusions, the 
authors advocated not administering any adjuvant treatment following surgery and 
comprehensive staging in patients with this stage and grade of disease [2].
Recently the results of two randomized European trials that included an observation arm 
have become available [3,4]. In the Italian study [3], patients with early-stage ovarian 
cancer were randomly assigned to receive either cisplatin or observation following 
surgery. Patients in both arms received salvage therapy on recurrence. A statistically 
significant difference in recurrence- free survival was found in favor of chemotherapy, 
but no difference in overall survival was demonstrated (overall survival: hazard ratio 
[HR] = 1.15 [95% confidence interval [CI] = 0.44 to 2.98]; recurrence-free survival: 
HR = 0.35 [95% CI = 0.14 to 0.89]). The authors suggested that salvage treatment 
was more effective in the observation arm than in the adjuvant chemotherapy arm and 
that, although patient numbers were small, these findings support a policy of deferring 
chemotherapy until the actual time of recurrence [3]. In the Scandinavian study [4], 
162 patients with early-stage ovarian carcinoma were randomly assigned to receive 
carboplatin or observation following surgery. No difference in disease-specific survival 
or disease-free survival was seen (disease-specific survival: HR = 0.94 [95% CI = 0.37 
to 2.36]; disease-free survival: HR = 0.98 [95% CI = 0.52 to 1.83]) [4]. However, both 
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the Italian and Scandinavian studies lacked the power to draw definitive conclusions 
and did not take into account the extent of the surgical staging of their study groups. 
The quality of surgical staging in ovarian cancer relates to the reliability of the diagnosis 
of early-stage disease because it has been well documented that approximately 24% of 
non-optimally staged patients with early-stage ovarian cancer actually harbor occult 
residual disease in the peritoneal cavity (stage III disease) [5–8].
In 1990 the European Organisation for Research and Treatment of Cancer–
Gynaecological Cancer Group (EORTC–GCG) initiated a randomized clinical trial 
comparing platinum-based adjuvant chemotherapy with no further treatment (i.e., 
observation) following surgery in patients with early-stage ovarian cancer. 
The study, called Adjuvant ChemoTherapy in Ovarian Neoplasm (ACTION), which ran 
between November 1990 and January 2000, was designed to have more statistical power 
than previous trials to detect a survival difference and to emphasize the completeness 
of surgical staging in the analysis of the endpoints of the study. At the same time, the 
International Collaborative Ovarian Neoplasm Collaborators initiated a similar trial 
(ICON1), the results of which are also published [9]. We report on the findings of the 
ACTION trial.
PATIENTS AND METHODS
Patients and Surgery 
Patients with International Federation of Gynecology and Obstetrics (FIGO) stages Ia–
Ib, grade II–III; all stages Ic and IIa, and all stages I–IIa with clear cell epithelial cancer of 
the ovary were eligible for the study [10,11]. Surgical treatment had to consist of total 
abdominal hysterectomy and bilateral salpingo-oophorectomy, followed by surgical 
staging. In cases of stage Ia cancer, unilateral salpingo-oophorectomy followed by 
surgical staging was permitted. This kind of conservative surgery has been shown to 
be adequate treatment for women with stage Ia disease who wish to preserve fertility 
[12,13]. Patients with a prior or concomitant second malignancy were excluded, as were 
patients with a World Health Organization (WHO) performance status of more than 
3, previous treatment with chemotherapy or radiation therapy, expected inadequacy 
of follow-up, and an interval of more than 6 weeks between surgical staging procedure 
and randomization. The Institutional Review Board of each participating center had to 
approve the study, and informed consent of each patient was a prerequisite. 
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Surgical Staging 
Surgical staging had to consist of at least careful inspection and palpation of all 
peritoneal surfaces, with biopsies of any suspect lesions, such as adhesions adjacent to 
the ovarian tumor. 
However, far more comprehensive staging was strongly advised, including omentectomy; 
peritoneal washings; blind biopsies from the peritoneum in the pelvis (pouch of Douglas, 
bladder, pelvic sidewalls), the paracolic gutters, and the right hemidiaphragm; and iliac 
and peri-aortic lymph node sampling. If all of these staging requirements were met, the 
staging performance was considered to be optimal. Three other, less comprehensive 
staging categories were defined: modified, minimal, and inadequate (Table 1). Strict 
guidelines were also given for the microscopic assessment of histologic cell type and for 
the assessment of tumor differentiation, according to WHO criteria [10]. 
Table 1. Requirements for surgical staging following bilateral salpingo-oophorectomy and total abdominal 
hysterectomy* 
Surgical staging category      Staging guidelines
  Optimal Inspection and palpation of all peritoneal surfaces; biopsies of any suspect 
lesions for metastases; peritoneal washing; infracolic omentectomy; (blind) 
biopsies of right hemidiaphragm, of right and left paracolic gutter, of pelvic 
sidewalls, of ovarian fossa, of bladder peritoneum, and of cul-de-sac; sampling 
of iliac and peri-aortic lymph nodes. 
  Modified Everything between optimal and minimal staging.
  Minimal Inspection and palpation of all peritoneal surfaces and the retroperitoneal area; 
biopsies of any suspect lesions for metastases; peritoneal washing; infracolic 
omentectomy.
  Inadequate Less than minimal staging but at least careful inspection and palpation of all 
peritoneal surfaces and the retroperitoneal area; biopsies of any suspect lesions 
for metastases.
* Patients with stage Ia disease who wished to preserve fertility were permitted to have only a unilateral salpingo-
oophorectomy. 
Randomization 
Patients were centrally randomly assigned to either the adjuvant chemotherapy arm or 
the observation arm by a computer program, using a minimization procedure, at the 
EORTC Data Center in Brussels. Randomization was stratified according to institution, 
FIGO stage, and grade of tumor differentiation. 
Adjuvant Chemotherapy 
Treatment in the adjuvant chemotherapy arm had to consist of at least four courses 
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of a platinum-based regimen following surgery; however, six courses of treatment were 
recommended. 
Single-agent platinum chemotherapy was also allowed as well as combination 
regimens. In the case of cisplatin, the required dose was 75 mg/m², and for carboplatin 
the required dose was 350 mg/m². Dose modifications in the case of drug toxicity were 
given when appropriate. Each center had to define its adjuvant chemotherapy regimen 
in advance and had to remain with that regimen for the duration of the trial. After 
surgery, patients in the observation arm were not treated again until recurrence. Tumor 
recurrence had to be confirmed cytologically or histologically. 
Patients in the observation arm who had tumor recurrence were given the same chemo-
therapy regimen that their particular center was using in the adjuvant chemotherapy arm. 
Statistical Analysis 
Analysis of results was on an intention-to-treat basis. The primary endpoint was overall 
survival, and the secondary endpoint was recurrence-free survival. Time-to-event analyses 
were based on the Kaplan–Meier method [14] and events were compared using the 
log-rank test. Prognostic factor analysis used the Cox proportional hazards regression 
model, after necessary assumptions were met, to determine statistically significant 
covariates, such as FIGO stage, tumor grade, histologic cell type, completeness of 
surgical staging, age, tumor marker carcino antigen 125 (CA 125) level and performance 
status. Differences in relative size of treatment effect between subgroups of staging 
performance were tested using a chi-square (χ²) test for interaction. 
Because of the relatively long life expectancy of patients with early-stage ovarian 
carcinoma and the small expected improvements in survival, the sample size was 
set, more or less arbitrarily, to 1000 or more patients. An independent interim data-
monitoring committee assessed the data and the progress of the study at fixed intervals. A 
single independent data-monitoring committee monitored the combined accumulating 
data from ACTION and the parallel trial (ICON1). Interim analyses were interpreted 
by using conservative statistical significance tests. If the P value for the comparison of 
survival between treatment arms fell below 0.01, consideration was given to stopping 
the trial. Because patient accrual took longer than expected, the committee decided 
to close the study in 2000, before the target number of patients was accrued. Audits 
by an independent quality control panel were done during the course of the study to 
verify the quality of the data. A separate publication on the findings of this panel is 
in preparation, but preliminary analysis has confirmed the reliability of the surgical 
staging data. 




Between November 1990 and January 2000, a total of 448 patients were accrued to 
the trial by 40 centers from nine European countries. Analysis is complete through 
March 26, 2001 (Fig. 1). Table 2 shows the clinical and tumor characteristics of the 
patients in both trial arms. The majority of patients in the chemotherapy arm received 
cisplatin combined with cyclophosphamide (102 patients or 47%) or single-agent 
carboplatin (71 patients or 33%). The various clinical and pathologic risk factors were 




 224 allocated no adjuvant 224 allocated adjuvant
 treatment (observation) chemotherapy
 (14 patients received adjuvant (13 patients never received
 chemotherapy) chemotherapy)
 6 patients lost to follow-up 3 patients lost to follow-up
 (median follow-up 66 months) (median follow-up 66 months)
 alive no recurrence 150 (69%) alive no recurrence 175 (79%)
 alive no recurrence 23 (11%) alive no recurrence 13 (6%)
 dead no recurrence 8 (4%) dead no recurrence 5 (2%)
 dead after recurrence 37* (17%) dead after recurrence 26 (12%)
  dead from unknown causes 2 (1%)
Figure 1. CONSORT diagram of the trial profile of the European Organisation for Research and Treatment of 
Cancer (EORTC)–Adjuvant ChemoTherapy In Ovarian Neoplasm (ACTION) trial. 
*In one patient, no recurrent disease was suspected before the time of death. 
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Table 2. Clinical and tumor characteristics in patients with early ovarian cancer (stage I–IIa) by treatment arm* 
                Observation  Adjuvant chemotherapy 
Characteristic                (N =224)           (N =224)
Age, y (median; range)  55 (22–77) 54 (18–84) 
Performance status†, n (%) 
   0  199 (89)  188 (84) 
   1  21 (9)  34 (15) 
   2  3 (1)  2 (1) 
   Missing 1 (1) 0 (0) 
FIGO stage‡, n (%)
   Ia  76 (33)  79 (35) 
   Ib  18 (8)  19 (8) 
   Ic, ovarian surface  28 (13) 22 (10) 
   Ic, capsule ruptured  52 (23)  64 (29) 
   Ic, ascites/malignant washing 33 (15)  24 (11) 
   IIa  15 (7)  16 (7) 
   Missing  2 (1) 0 (0) 
  
Tumor grade§, n (%) 
   Well differentiated  28 (12)  26 (12) 
   Moderately differentiated  114 (51)  114 (50) 
   Poorly differentiated  78 (35) 78 (35) 
   Unknown  2 (1)  6 (3) 
   Missing  2 (1) 0 (0) 
Histologic cell type, n (%) 
   Serous 74 (33) 82 (37) 
   Mucinous  35 (16)  42 (19) 
   Endometrioid  72 (32)  48 (21) 
   Clear-cell  26 (12)  37 (17) 
   Undifferentiated  5 (2)  3 (1) 
   Other  9 (4)  7 (3) 
   Missing  3 (1)  5 (2) 
CA 125, n (%) 
   Normal  55 (24) 73 (33) 
   Abnormal  116 (52)  0 (40) 
   Not done  51 (23)  7 (25) 
   Missing  2 (1)  4 (2) 
Surgical staging performance, n (%) 
   Optimal  75 (34)  76 (34) 
   Modified  68 (30) 70 (31) 
   Minimal  60 (27)  54 (24) 
   Inadequate  19 (9)  24 (11) 
   Missing 2 (1) 0 (0) 
*Missing = patient information was missing. 
†Performance status was in accordance with World Health Organization guidelines [15]. 
‡FIGO = International Federation of Gynecology and Obstetrics staging system [11]. 
§Tumor grade was in accordance with World Health Organization grading criteria [10]. 
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chemotherapy, and 14 patients in the adjuvant chemotherapy arm did not. The reasons 
for these protocol violations were morbidity, disease progression, administrative error, 
and patient refusal. Follow-up ranged from 3 months to 9 years, with a median follow-
up of 5.5 years. Nine patients were lost to follow-up, six in the observation arm and 
three in the chemotherapy arm. 
During the follow-up period 100 recurrences were detected, 60 in the observation arm and 
40 in the chemotherapy arm. The incidence of recurrence in the locoregional, extrapelvic, 
and combined pelvic and extrapelvic sites in the observation and chemotherapy arms 
was 33%, 47%, and 20% and 35%, 50%, and 15%, respectively (Table 3). Overall, 78 
patients died, 45 in the observation arm and 33 in the chemotherapy arm. Sixty-three of 
the 78 deaths (81%) were due to ovarian cancer; this percentage was similar between the 
two trial arms. Eight patients in the observation arm died of causes other than ovarian 
cancer: two of heart failure, three of other malignancies, two of cerebrovascular accident, 
and one of respiratory failure. Five patients in the chemotherapy arm died of causes 
other than ovarian cancer: two of heart failure, one of cerebrovascular accident, one 
of idiopathic thrombocytopenia, and one of pulmonary thromboembolism following a 
bone fracture. Two patients in the chemotherapy arm died of unknown causes. 
Table 3. Site of disease recurrence in patients with early ovarian cancer by treatment arm 
 Adjuvant chemotherapy  Observation    Total 
Variable  (N = 224)  (N = 224)  (N = 448) 
No recurrence, n (%)  184 (82)  164 (73)  348 (78) 
Recurrence, n (%)   40 (18)   60 (27)  100 (22) 
Pelvic   14 (6)   20 (9)   34 (8) 
Extrapelvic   20 (9)   28 (13)   48 (11) 
Both (pelvic + extrapelvic)    6 (3)   12 (5)   18 (4) 
Survival Data 
Kaplan–Meier analysis of overall survival yielded 5-year survival figures in the observation 
and the adjuvant chemotherapy arms of 78% and 85%, respectively, a difference of 7% 
(95% CI = –1.08% to 15.72%). The difference in overall survival between the two arms 
was not statistically significant, as depicted in Fig. 2 (HR = 0.69 (95% CI = 0.44 to 
1.08); P = 0.10). The Kaplan–Meier curves for recurrence-free survival in both arms 
are shown in Fig. 3. Patients in the adjuvant chemotherapy arm had statistically better 
recurrence-free survival than patients in the observation arm, with an HR of 0.63 (95% 
CI = 0.43 to 0.92; P = 0.02). These results translate into 5-year survival figures of 68% 
for patients in the observation arm and 76% for patients in the adjuvant chemotherapy 
arm, an improvement in recurrence-free survival of 8% (95% CI = –0.88% to 18.04%). 
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Figure 2. 
Kaplan–Meier curves for overall survival in patients with early-stage ovarian cancer.  
Adjuvant chemotherapy patients (n = 224) (solid line) were those patients who received 
immediate adjuvant chemotherapy. Observation patients (n = 224) (dotted line) were those 
patients who were observed until adjuvant chemotherapy was indicated.  
The hazard ratio is 1.45 (95% confidence interval [CI] = 0.93 to 2.27, P = 0.10 using  
the log-rank test). These results translate into 5-year overall survival figures of 78% for 
patients in the observation arm and 85% for patients in the adjuvant chemotherapy arm, a 
difference of 7% (95% CI = –1.08% to 15.72%). N = number of patients; O = number of 
observations (events).  
Of the 100 patients who had tumor recurrence, 66 died (66%; 62 deaths were due to ovarian 
cancer). Among the optimally staged patients, six of the 13 (46%) patients who had tumor  
recurrence in the observation arm died and nine of the 12 (75%) patients who had tumor 
recurrence in the chemotherapy arm died. Among the non-optimally staged patients, the 
percentages were different; 33 of the 47 (70%) patients who had tumor recurrence in the 
observation arm died, and 18 of the 28 (64%) patients who had tumor recurrence in the 






Figure 2. Kaplan–Meier curves for overall survival in patients with early-stage ovarian cancer. Adjuvant 
chemotherapy patients (n = 224) (solid line) were those patients who received immediate adjuvant 
chemotherapy. Observation patients (n = 224) (dotted line) were those patients who were observed until 
adjuvant chemotherapy was indicated. 
The hazard ratio is 1.45 (95% confidence interval [CI] = 0.93 to 2.27, P = 0.10 using the log-rank test). These 
results translate into 5-year overall survival figures of 78% for patients in the observation arm and 85% for 
patients in the adjuvant chemotherapy arm, a difference of 7% (95% CI = –1.08% to 15.72%). N = number of 
patients; O = number of observations (events). 
Of the 100 patients who had tumor recurrence, 66 died (66%; 62 deaths were due to ovarian cancer). Among 
the optimally staged patients, six of the 13 (46%) patients who had tumor recurrence in the observation arm 
died and nine of the 12 (75%) patients who had tumor recurrence in the chemotherapy arm died. Among the 
non-optimally staged patients, the percentages were different; 33 of the 47 (70%) patients who had tumor 
recurrence in the observation arm died, and 18 of the 28 (64%) patients who had tumor recurrence in the 
chemotherapy arm died. 
Prognostic Factors and Survival 
To determine possible prognostic factors for overall and recurrence-free survival, we 
performed univariate and multivariable analyses of possible risk factors apart from 
treatment on the survival data. In Table 4, the univariate and multivariable analyses of 
possible risk factors apart from treatment are summarized. 
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CA 125 analysis was performed in too few of the patients to be considered in the 
multivariable analysis. FIGO stage was not a statistically significant prognostic factor. 
Staging adequacy and tumor grade were statistically significant prognostic factors for 
overall survival and recurrence-free survival in the univariate and multivariable analysis. 
Histologic cell type was a statistically significant prognostic factor only for overall 
survival in the univariate and multivariable analysis. 
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Figure 3. 
Kaplan–Meier curves for recurrence-free survival in patients with early-stage ovarian  
cancer. Adjuvant chemotherapy patients (n = 224) (solid line) were those patients who 
received immediate adjuvant chemotherapy.  
Observation patients (n = 224) (dotted line) were those patients who were observed until 
adjuvant chemotherapy was indicated. The hazard ratio is 1.59 (95% confidence interval [CI] 
= 1.09 to 2.31, P = 0.02 using the log-rank test) in favor of adjuvant chemotherapy.  
These results translate into 5-year recurrence-free survival igures of 68% for patients in the 
observation arm and 76% for patients in the adjuvant chemotherapy arm, a difference of 8% 
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Adjuvant chemotherapy patients (n = 224) (solid line) were those patients who received immediate adjuvant 
chemotherapy. 
Observation patients (n = 224) (dotted line) were those patients who were observed until adjuvant 
chemotherapy was indicated. The hazard ratio is 1.59 (95% confidence interval [CI] = 1.09 to 2.31, P = 0.02 
using the log-rank test) in favor of adjuvant chemotherapy. 
These results translate into 5-year recurrence-free survival figures of 68% for patients in the observation arm 
and 76% for patients in the adjuvant chemotherapy arm, a difference of 8% (95% CI = 0.88% to 18.04%). 
N = number of patients; O = number of observations (events). 
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Because staging adequacy was a statistically significant prognostic factor, we investigated 
survival by different categories of staging (Table 1). Four categories were defined, and 
the survival curves are shown in Fig. 4. However, for further survival analyses, these 
categories were dichotomized into just two categories: optimal and non-optimal. This 
particular dichotomization was done a priori and for reasons of clarity. From a clinical 
point of view, optimal staging would be easy to define; that is, all staging steps had 
to be performed. The other staging categories— modified, minimal, and inadequate 
(regardless of what and how many staging steps were omitted) were regarded as non-
optimal. 
Of the 448 patients, 151 were optimally staged (observation arm, 75; chemotherapy 
arm, 76) and 295 were non-optimally staged (observation arm, 147; chemotherapy 
arm, 148) and in two patients, the staging status was unknown (Table 2). The various 
baseline characteristics were well balanced among the different staging categories 
(data not shown). In the observation arm, patients who underwent non-optimal 
surgical staging had statistically significantly worse overall survival (Fig. 5, A) (HR = 
2.31, 95% CI = 1.08 to 4.96; P = 0.03) and recurrence-free survival (Fig. 5, C) (HR = 
1.82, 95% CI = 1.02 to 3.24; P = 0.04) than the optimally staged patients. However, 
no difference in overall or recurrence-free survival was evident in the patients in the 
adjuvant chemotherapy arm (Fig. 5, B and D). 
Table 4. Prognostic factors that were identified in the univariate and multivariable analyses* 
       Univariate   Multivariable 
  P  P 
Variable  HR (95% CI)  value†  HR (95% CI)  value‡ 
Overall survival 
Surgical staging  2.24 (1.29 to 3.90)  0.004  2.05 (1.14 to 3.67)  0.04 
Tumor grade  1.64 (1.05 to 2.56) 0.03  1.62 (1.03 to 2.54)  0.03 
Histologic cell type  1.79 (1.11 to 2.88)  0.02  1.72 (1.06 to 2.79) 0.02 
Recurrence-free survival 
Surgical staging  2.06 (1.25 to 3.39)  0.004  1.96 (1.18 to 3.26) 0.009 
Tumor grade  1.85 (1.28 to 2.69)  0.001  1.86 (1.28 to 2.70)  0.001 
Histologic cell type  N.S.   N.S. 
* HR = hazard ratio; CI = confidence interval. Surgical staging = inadequate versus minimal, modified, and optimal. 
Tumor grade was in accordance with World Health Organization grading criteria (10). Histologic cell type = mucinous/
endometrioid versus serous, clear-cell, undifferentiated, and other (rare) histology. N.S. = not statistically significant. 
†P value was determined using the Cox proportional hazards regression model. 
‡P value was determined using the Cox proportional hazards regression model. 
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Extending this subgroup analysis further by looking at the optimal and non-optimal 
staging groups separately, no difference in overall survival between the observation 
arm and the chemotherapy arm was found in the optimally staged patients (Fig. 6, A), 
whereas a statistically significant difference in overall survival between the two arms 
was demonstrated in the non-optimally staged patients (Fig. 6, B) (HR = 1.75, 95% CI 
= 1.04 to 2.95; P = 0.03). A similar phenomenon was seen for recurrence-free survival 
(optimally staged patients: HR =1.14, 95% CI = 0.54 to 2.39; P = 0.7 [Fig. 6, C]; non-
optimally staged patients: HR = 1.78, 95% CI = 1.15 to 2.77; P = 0.009 [Fig. 6, D]). 
However, interactions between treatment effect and the staging subgroups did not 
reach statistical significance (HR = 2.18, 95% CI . 0.74 to 6.38; P = 0.15; Fig. 7). 
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Figure 4. 
Kaplan–Meier curves for overall survival in patients with early-stage ovarian carcinoma by 
staging type. Optimal staging (n = 151) (solid line), modified staging (n = 138) (solid dotted 
line), minimal staging (n = 114) (fine dotted line), and inadequate staging (n = 43) (solid/fine 
dotted line) are in accordance with the staging guidelines presented in Table 1. The hazard 
ratio is 2.17 (95% confidence interval [CI] = 1.25 to 3.76; P = 0.005 using the log-rank test) 
in favor of optimal staging. N = number of patients; O = number of observations (events).  
 
 
Figure 4. Kaplan–Meier curves for overall survival in patients with early-stage ovarian carcinoma by staging 
type. Optimal staging (n = 151) (solid line), modified staging (n = 138) (solid dotted line), minimal staging 
(n = 114) (fine dotted line), and inadequate staging (n = 43) (solid/fine dotted line) are in accordance with 
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Figure 5. 
Kaplan–Meier curves for overall and recurrence-free survival in patients with  
early-stage ovarian cancer by staging type. Optimal staging (n = 75 in the observation  
arm and n = 76 in the chemotherapy arm) (solid line) and non-optimal staging (modified,  
minimal, inadequate staging categories combined) (n = 147 in the observation arm  
and n = 148 in the chemotherapy arm) (dotted line) are in accordance with the staging  
guidelines presented in Table 1. N = number of patients; O = number of observations  
(events). A) Overall survival in the observation arm. The hazard ratio [HR] = 2.31  
(95% confidence interval [CI] = 1.06 to 4.96, P = 0.03 using the log-rank test) in  
favor of optimal staging. B) Overall survival in the adjuvant chemotherapy arm. HR = 1.06 
(95% CI = 0.51 to 2.23, P = 0.9 using the log-rank test). C) Recurrence-free survival in the 
observation arm. HR = 1.82 (95% CI =1.02 to 3.24, P = 0.04 using the log-rank test) in favor 
of optimal staging. D) Recurrence-free survival in the adjuvant chemotherapy arm. HR 1.17 
(95% CI = 0.0.62 to 2.22, P = 0.6 using the log-rank test).  
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Figure 5. 
Kaplan–Meier curves for overall and recurrence-free survival in patients with  
early-stage ovarian cancer by staging type. Optimal staging (n = 75 in the observation  
arm and n = 76 in the chemotherapy arm) (solid line) and non-optimal staging (modified,  
minimal, inadequate staging categories combined) (n = 147 in the observation arm  
and n = 148 in the chemotherapy arm) (dotted line) are in accordance with the staging  
guidelines presented in Table 1. N = number of patients; O = number of observations  
(events). A) Overall survival in the observation arm. The hazard ratio [HR] = 2.31  
(95% confidence interval [CI] = 1.06 to 4.96, P = 0.03 using the log-rank test) in  
favor of optimal staging. B) Overall survival in the adjuvant chemotherapy arm. HR = 1.06 
(95% CI = 0.51 to 2.23, P = 0.9 using the log-rank test). C) Recurrence-free survival in the 
observation arm. HR = 1.82 (95% CI =1.02 to 3.24, P = 0.04 using the log-rank test) in favor 
of optimal staging. D) Recurrence-free survival in the adjuvant chemotherapy arm. HR 1.17 
(95% CI = 0.0.62 to 2.22, P = 0.6 using the log-rank test).  
 
 
C) Recurrence-free survival in the observation arm. HR = 1.82 (95% CI =1.02 to 3.24, P = 0.04 using the log-
rank test) in favor of optimal staging. D) Recurrence-free survival in the adjuvant chemotherapy arm. HR 1.17 
(95% CI = 0.0.62 to 2.22, P = 0.6 using the log-rank test). 
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Figure 6. Kaplan–Meier curves for overall and recurrence-free survival in patients with early-stage ovarian 
cancer by treatment arm. 
Chemotherapy patients (solid line) were those patients who received immediate adjuvant chemotherapy 
(n = 76 in optimally staged arm, and n = 148 in non-optimally staged arm). Observation patients (dotted 
line) were those patients who were observed until chemotherapy was indicated (n = 75 in optimally staged 
arm, and n = 147 in non-optimally staged arm). N = number of patients; O = number of observations (events).
A) Overall survival in the optimally staged patients. The hazard ratio (HR) = 0.81 (95% confidence interval 
[CI] = 0.32 to 2.05, P = 0.7 using the log-rank test). B) Overall survival in the non-optimally staged patients. 
HR = 1.75 (95% CI = 1.04 to 2.95, P = 0.03 using the log-rank test) in favor of adjuvant chemotherapy. 
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Figure 6. 
Kaplan–Meier curves for overall and recurrence-free survival in patients with early-stage 
ovarian cancer by treatment arm.  
Chemotherapy patients (solid line) were those patients who received immediate adjuvant 
chemotherapy (n = 76 in optimally staged arm, and n = 148 in non-optimally staged arm). 
Observation patients (dotted line) were those patients who were observed until chemotherapy 
was indicated (n = 75 in optimally staged arm, and n = 147 in non-optimally staged arm).  
N = number of patients; O = number of observations (events). A) Overall survival in the 
optimally staged patients. The hazard ratio (HR) = 0.81 (95% confidence interval [CI] = 0.32 
to 2.05, P = 0.7 using the log-rank test). B) Overall survival in the non-optimally staged 
patients. HR = 1.75 (95% CI = 1.04 to 2.95, P = 0.03 using the log-rank test) in favor of 
adjuvant chemotherapy. C) Recurrence-free survival in the optimally staged patients. HR = 
1.14 (95% CI = 0.54 to 2.93, P = 0.7 using the log-rank test).  D) Recurrence-free survival in 
the non-optimally staged patients. HR = 1.78 (95% CI = 1.51 to 2.77, P = 0.009 using the log-
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Observation patients (dotted line) were those patients who were observed until chemotherapy 
was indicated (n = 75 in optimally staged arm, and n = 147 in non-optimally staged arm).  
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Figure 6. 
Kaplan–Meier curves for overall and recurrence-free survival in patients with early-stage 
ovarian cancer by treatment arm.  
Chemotherapy patients (solid line) were those patients who received immediate adjuvant 
chemotherapy (n = 76 in optimally staged arm, and n = 148 in non-optimally staged arm). 
Observation patients (dotted line) were those patients who were observed until chemotherapy 
was indicated (n = 75 in optimally staged arm, and n = 147 in non-optimally staged arm).  
N = number of patients; O = number of observations (events). A) Overall survival in the 
optimally staged patients. The hazard ratio (HR) = 0.81 (95% confidence interval [CI] = 0.32 
to 2.05, P = 0.7 using the log-rank test). B) Overall survival in the non-optimally staged 
patients. HR = 1.75 (95% CI = 1.04 to 2.95, P = 0.03 using the log-rank test) in favor of 
adjuvant chemotherapy. C) Recurrence-free survival in the optimally staged patients. HR = 
1.14 (95% CI = 0.54 to 2.93, P = 0.7 using the log-rank test).  D) Recurrence-free survival in 
the non-optimally staged patients. HR = 1.78 (95% CI = 1.51 to 2.77, P = 0.009 using the log-
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DISCUSSION
The present study provides evidence that adjuvant chemotherapy delays disease 
recurrence in patients with early-stage ovarian cancer, of whom two-thirds (n =297) had 
undergone non-optimal surgical staging. For overall survival, however, no statistically 
significant differences were observed. 
In addition to the well known risk factors for overall and recurrence-free survival, such as 
tumor grade and histologic cell type [16], the completeness of surgical staging was found 
to be an independent prognostic factor. The impact of surgical staging on prognosis 
is not surprising, because the extent of staging influences the likelihood of residual 
disease. Optimal surgical staging minimizes the likelihood of residual stage III disease, 
and incomplete surgical staging increases the possibility of hidden occult cancer in the 
peritoneal cavity. The finding that completeness of surgical staging is an independent 
prognostic factor is not completely new. For example, in 1992 the Department of 
Obstetrics and Gynecology at Yale University compared expert and comprehensive 
surgery (i.e., complete surgical staging) in early-stage ovarian cancer with incomplete 
surgical staging and tumor removal [17]. Although the number of patients in that study 
was small, a statistically significant survival advantage was demonstrated in favor of 
the completely staged group. More recently, Italian investigators have also identified 
the extent of surgical staging with early-stage ovarian carcinoma as an independent 
prognostic factor in their multivariable analysis [18]. 
In the current study, patients in the observation arm who were optimally staged had 
statistically significantly better overall and recurrence-free survival than patients who 
were non-optimally staged (Fig. 5, A and C). However, the poor prognosis of the non-
optimally staged patients could be corrected by administering adjuvant chemotherapy 
(Fig. 5, B and D). This finding suggests that adjuvant chemotherapy in early-stage 
ovarian cancer may work predominantly by affecting small-volume or microscopic 
tumor implants or metastases that remain unnoticed at the time of surgical staging. 
This hypothesis is supported by the finding that chemotherapy improved both overall 
and recurrence-free survival in the non-optimally staged patients (i.e., those patients 
who may have had residual disease) and not in the optimally staged patients (i.e., 
those patients who had only a minimal chance of residual disease) (Fig. 6, B and D). 
The finding that adjuvant chemotherapy is effective in non-optimally staged patients 
might also explain the results of the ICON1 trial [9] and the combined ICON1/ACTION 
analysis [19], in which the majority of patients were most probably not optimally staged. 
Although FIGO stage is generally a well known risk factor for survival of patients with 
ovarian cancer, it was not found to be a prognostic factor in this study. For example, 
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stage Ic disease was not associated with a higher risk of recurrence or death compared 
with moderately and poorly differentiated stages Ia and Ib disease (data not shown). 
In addition, in a recent meta-analysis of more than 1500 cases of early-stage ovarian 
cancer, Vergote et al. [16] found that stage Ic disease had a prognosis similar to that 
of stage Ib disease. Thus, these findings might be an important consideration when 
redefining high-risk early-stage ovarian cancer. 
Salvage treatment of patients with recurrent disease showed a difference in salvage 
rate (i.e., the percentage of patients successfully treated for tumor recurrence) between 
the optimally staged and the non-optimally staged patients. In the non-optimally 
staged patients, the salvage rate in the observation and the adjuvant chemotherapy 
arms was similar (70% and 64%, respectively). In the optimally staged patients, salvage 
treatment with adjuvant chemotherapy was more successful in the observation arm 
than in the adjuvant chemotherapy arm (75% and 46%, respectively). The number of 
patients involved in this analysis was small, but it is of interest that the same difference 
in the effectiveness of chemotherapy salvage treatment was found in the Italian Gruppo 
Interregionale Collaborative Oncology Group (GICOG) study, in which patients also 
underwent complete surgical staging [3]. If this difference in the effectiveness of salvage 
treatment were to be observed in larger studies, it would give additional support to a 
policy of postponing chemotherapy until the time of actual tumor recurrence, providing 
that optimal surgical staging had been performed. 
Like other analyses of this kind, this study has several potential limitations. First, 
the ACTION trial was not specifically designed to compare different surgical staging 
procedures, and patients were not prospectively stratified according to the various 
surgical staging categories. Retrospective stratification, however, showed a well-
balanced distribution of the four staging categories between the two treatment arms 
(data not shown) and no differences in the distribution of other risk factors, such as 
tumor grade and histologic cell type, between optimally and non-optimally staged 
patients. Second, the numbers of patients become increasingly smaller when performing 
subgroup analyses. 
Although this study is the largest randomized trial in early-stage ovarian cancer in 
terms of the number of assessable patients, it still suffers from a limited sample size. 
Therefore, the interpretation of results should be made with sufficient care, because, 
although interactions of this kind are generally hard to detect, a lack of statistically 
significant differences between two groups does not necessarily imply equivalence. 
Statistical tests to analyze the potential interaction between the chemotherapy effect 
and the staging adequacy showed only trends and no proof (P = 0.15). In Fig. 7, a 
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graphic representation of this analysis can be seen. The hazard ratios of optimal and 
non-optimal staging regarding overall survival seem to be different, but statistical proof 
at a P = 0.05 level was prevented by the large 95% confidence interval in the optimally 
staged patients. The main determinant of the width of the 95% confidence interval is 
the number of events, and events were infrequent following complete surgical staging. 
It is, therefore, exactly the factor that has to be proven that is hampering the statistical 
ability to do so. 
This effect, the opposite of a self-fulfilling prophecy, sheds doubt on the possibility that 
stronger statistical proof will ever be feasible in terms of necessary numbers of patients. 
Although we have stressed the clinical significance of complete surgical staging of 
early-stage ovarian cancer, some concern may be raised about its feasibility in clinical 
practice. 
In the ACTION trial, even though strict guidelines for optimal surgical staging were 
set, only one-third of the patients were optimally staged according to the guidelines 
in Table 1. The reasons for this low number of patients actually receiving staging 
according to trial protocols are well known. Early-stage ovarian cancer often presents 
with symptoms mimicking a benign ovarian cyst. This clinical condition is then dealt 
with by surgeons with either a lack of knowledge of ovarian cancer spread or a lack of 
surgical experience (e.g., in lymph node sampling) [20,21]. The findings of this study 
underscore the clinical significance of surgical staging and will hopefully influence the 
current practice of referral and centralization to oncology centers of suspected early-
stage ovarian cancer patients. 
In conclusion, this trial studied patients who were completely and comprehensively 
(i.e., optimally) staged in only one-third of cases. Taking all patients into account, 
adjuvant chemotherapy statistically significantly improved recurrence-free survival, 
but no improvement was seen in overall survival. Tumor grade, histologic cell type, 
and completeness of surgical staging were independent prognostic factors. In the 
subgroup analysis of different staging adequacy, indications were found that adjuvant 
chemotherapy is not effective in optimally staged patients. Thus, we suggest that 
adjuvant chemotherapy in early-stage ovarian cancer is predominantly effective in 
patients with occult residual disease and that its effectiveness is dependent on the 
likelihood of remaining ovarian cancer spread. The adequacy of surgical staging is 
indicative of the likelihood of unappreciated residual cancer, and the observed benefit of 
adjuvant chemotherapy - primarily in non-optimally staged patients - may be indicative 
of a benefit of adjuvant chemotherapy only in patients with appreciable residual 
disease. In the next EORTC trial we will attempt to confirm the findings that adjuvant 
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chemotherapy in early-stage ovarian cancer, is not effective after optimal surgical 
staging. We are considering a trial protocol to randomly assign non-optimally staged 
patients into either restaging (i.e., to make the patient optimally staged) followed by 
observation or direct adjuvant chemotherapy without restaging. Because the two trial 
arms may be equivalent in terms of survival, quality-of-life issues will be an important 
endpoint of this study. 
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PURPOSE OF REVIEW
The treatment of early ovarian cancer has long been based on non-randomized studies 
and on a small number of randomized studies without sufficient power. Adjuvant 
chemotherapy is often given to high-risk patients, but the benefit of such an approach 
has never been proven and the definition of high-risk early ovarian cancer differs widely. 
Recently, the results of the two largest randomized clinical trials on early ovarian cancer 
became available. Both trials are discussed, and their results are related to the other 
relevant literature of the last three years.
RECENT FINDINGS 
A meta-analysis of over 1500 patients from the year 2001 confirmed tumor grade 
as a strong prognostic factor but it also demonstrated the adverse effect of capsule 
rupture before and during surgery. The Adjuvant ChemoTherapy in Ovarian Neoplasm 
trial (European Organisation for Research and Treatment of Cancer) randomized 448 
patients to either adjuvant chemotherapy following surgery or observation. 
Adjuvant chemotherapy improved overall survival and disease-free survival in non-
optimally staged patients but showed no benefit in optimally staged patients. The 
Medical Research Council International Collaborative Ovarian Neoplasm 1 trial 
randomized 477 patients in a similar way. Overall survival and disease-free survival were 
improved by adjuvant chemotherapy.
It was argued that the study population of the International Collaborative Ovarian 
Neoplasm 1 trial probably represents non-optimally staged patients, and this 
hypothesis explains why the results of this trial were in accord with those of the Adjuvant 
ChemoTherapy in Ovarian Neoplasm trial.
SUMMARY
The implications of these data are that a complete surgical staging is of utmost importance 
and should be pursued. In cases of non-optimal staging and contraindications for 
restaging, adjuvant chemotherapy is indicated to deal with unnoticed residual tumor 
deposits that exist in approximately 25% of cases.
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INTRODUCTION
The general notion of how to treat early epithelial ovarian cancer (stage I–IIa according 
to the International Federation of Gynaecology and Obstetrics) has long been based on 
a relatively small number of studies. The majority of these studies include retrospective 
observational reports, and, until 2000, only two relevant randomized clinical trials were 
available for consideration [1,2].
Young et al. [3], in a landmark study, had been the first to show that comprehensive 
restaging in patients with apparent early-stage ovarian carcinoma (on the basis of 
incomplete surgical staging) resulted in upstaging to stage III disease in 24% of cases 
(grade I tumors, 16%; grade III tumors, 46%). These findings were confirmed by a 
number of other investigators between 1985 and 1998 [4–9].
The importance of a complete surgical staging was also stressed by the group of Monza 
[10] in Italy, who found the completeness of surgical staging to be an independent 
prognostic factor in early ovarian cancer for overall survival as well as for disease-free 
survival (DFS).
Italian investigators also demonstrated that unilateral salpingo-oophorectomy instead 
of bilateral salpingooophorectomy and total abdominal hysterectomy can be regarded 
as adequate surgical staging in selected cases [11,12].
The only relevant randomized clinical trials with an observation arm were published in 
1990 and 2000 [1,2]. The first study randomized 81 comprehensively staged patients 
with low-risk ovarian cancer to either oral melphalan or observation. There was no 
difference in overall survival or DFS between the two arms [1].
In an Italian trial [2] involving patients with stage Ia or stage Ib G2 or G3 ovarian 
cancer, a randomization was performed between no treatment following complete 
surgical staging on the one hand and six courses of cisplatin (50 mg/m² every 28 days) 
on the other. A recent update of this trial with a median follow-up of more than 10 
years confirmed the results of the original publication: cisplatin significantly reduced 
the recurrence rate but not overall survival (overall survival in cisplatin arm, 88%; overall 
survival in observation arm, 82%) [12]. This difference was attributed to the fact that 
patients who relapsed from the observation arm were subsequently crossed over and 
treated with cisplatin. The chemo-naive patients from the observation arm responded 
better to cisplatin than the relapsed patients from the adjuvant chemotherapy arm. This 
observation is an important argument for postponing chemotherapy in early ovarian 
cancer until the time of actual tumor recurrence [2].
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On the basis of all these data, the importance of complete surgical staging was generally 
acknowledged. Furthermore, it was felt that adjuvant treatment for some groups of 
high-risk patients should be considered to reduce the recurrence rate, although a 
survival benefit had never been demonstrated. Because of the lack of randomized trials 
with sufficient numbers of patients, proof of the benefits of adjuvant treatment was not 
available. It was also realized that in routine practice the complete surgical staging of all 
patients with presumed early ovarian cancer is difficult to pursue [13,14].
RANDOMIZED CLINICAL TRIALS IN 2000–2003 
Recently, the results of three randomized clinical trials containing an observation arm 
following surgery were published; the fourth paper was a case-based meta-analysis of 
two of these studies [15-18].
In a Scandinavian trial [15], patients were randomly assigned to receive either 
carboplatin (n = 81) or observation (n = 81) after surgery. No differences in overall 
survival or DFS between the two arms were found (hazard ratio of DFS, 0.98, 95% 
confidence interval, 0.52–1.83; hazard ratio of overall survival, 0.94, 95% confidence 
interval, 0.36–2.36). Apart from tumor grade, aneuploidy was found to be a strong and 
independent prognostic factor [15].
The Adjuvant ChemoTherapy in Ovarian Neoplasm (ACTION) trial [16] was a 
multicenter European trial, also randomizing patients with early ovarian cancer to either 
observation following surgery or adjuvant chemotherapy. The main characteristics of 
this trial are summarized in Table 1 [16,17]. The inclusion criteria defined the ACTION 
population as having median to high-risk early ovarian cancer. Much emphasis was 
devoted to the surgical staging procedure in order to define the early-stage condition 
of the study population as far as possible. A total of 448 patients were involved: 224 
were in the observation arm, and 224 were in the chemotherapy arm. Despite the 
strict guidelines for optimal surgical staging, only 151 (34%) patients were found to 
have been optimally staged and 297 (66%) patients were considered as non-optimally 
staged. Overall survival was not statistically different between the observation arm and 
the chemotherapy arm (hazard ratio, 0.69; 95% confidence interval, 0.44–1.08; P = 
0.10). DFS was significantly better in the chemotherapy arm (hazard ratio, 0.63; 95% 
confidence interval, 0.43–0.72; P = 0.02).
Multivariate analysis revealed the histological cell type, the tumor grade, and the 
completeness of surgical staging as independent prognostic factors. In the observation 
arm, overall survival and DFS were significantly better for the optimally staged patients. 
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Table 1. Main characteristics and results of two randomized clinical trials on early ovarian cancer [16,17]
 EORTC ACTION trial MRC ICON1 trial
No. of patients 448 477
Randomization Observation versus at least four 
courses of platinum-containing 
chemotherapy
Observation versus at least four 
courses of platinum-containing 
chemotherapy
Entry criteria Stage Ia or Ib, G2 or G3, all 
stages Ic or IIa, all clear-cell 
cancer Ia–IIa; epithelial ovarian 
cancer
Doubt of the attending physician as 
to whether chemotherapy would be 
indicated following macroscopic tumor 
resection of epithelial ovarian cancer
Definition of relapse Histologically or cytologically 
confirmed
Clinically defined
Statistical analysis Intention-to-treat basis Intention-to-treat basis
Median duration of follow-up 66 months 51 months
Staging recommendations Detailed staging guidelines in 
the protocol;complete staging 
strongly recommended
No staging guidelines given
Completeness of staging 
monitored? 
Yes No
Guidelines for pathology Given Not given
assessment of tumorgrade 
and cell type 
Central pathology review? No No
Staging performance
   Optimal 
   Non-optimal 
5-Year overall survival
   Observation arm 
   Chemotherapy arm 
5-Year disease-free survival
   Observation arm 













Optimally staged vs non-optimally staged patients
   Observation
   x S 
   x DFS
   Chemotherapy
   x S
   x DFS 
HR 2.31 (1.06–4.96)* 
HR 1.82 (1.02–3.24)*
HR 1.06 (0.51–2.23)







   x S 
   x DFS 
HR 0.81 (0.32–2.05)




   x S 
   x DFS 
HR 1.75 (1.04–2.95)* 
HR 1.78 (1.51–2.77)** 
Unknown
Unknown  
ACTION, Adjuvant Chemotherapy in Ovarian Neoplasm; DFS, disease-free survival; EORTC, European Organization 
for Research and Treatment of Cancer; HR, hazard ratio; ICON1, International Collaborative Ovarian Neoplasm 1; 
MRC, Medical Research Council; S, overall survival. *P < 0.05 log rank test; **P < 0.01 log rank test.
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In the chemotherapy arm, this difference had disappeared (Table 1). In the non-optimally 
staged patients, overall survival and DFS were significantly better for the patients receiving 
adjuvant chemotherapy. In the optimally staged patients, there was no difference at all 
and the curves were identical (Table  1). The conclusion of the ACTION authors was 
that adjuvant chemotherapy may work predominantly by affecting small-volume or 
microscopic tumor deposits that remain unnoticed at the time of non-optimal surgical 
staging and that the benefits of adjuvant chemotherapy seem to be limited to non-
optimally staged patients with a higher risk of unappreciated residual disease.
The British International Collaborative Ovarian Neoplasm 1 (ICON1) trial [17] started 
one year later than the ACTION trial and used a similar study design. The most important 
characteristics of the ICON1 trial are also summarized in Table 1. In total, 477 patients 
were entered into the trial: 241 were in the chemotherapy arm, and 236 were in the 
observation arm. Overall survival was significantly better in the chemotherapy arm 
(hazard ratio, 0.66, 95% confidence interval, 0.45–0.97; P = 0.03) and the same was 
true for DFS (hazard ratio, 0.65; 95% confidence interval, 0.46–0.91, P = 0.01). The 
conclusions of the ICON1 collaborators were that adjuvant chemotherapy significantly 
prolonged overall survival and DFS in this group of patients, and that all patients 
with early-stage ovarian carcinoma should be considered for adjuvant chemotherapy 
following surgery [17].
Because of the difficulties in obtaining sufficient numbers of patients in the ICON1 
and ACTION trials, it was decided during the course of the two studies to perform a 
case-based meta-analysis of the combined patient material. This analysis was called 
ACTICON [18]. Adjuvant chemotherapy significantly improved overall survival (hazard 
ratio, 0.67; 95% confidence interval, 0.50–0.90; P = 0.008) and DFS (hazard ratio, 
0.64; 95% confidence interval, 0.50–0.82; P = 0.001). Five-year overall survival was 74% 
in the observation arm and 82% in the chemotherapy arm. Five-year DFS was 65% in the 
observation arm and 76% in the chemotherapy arm. The conclusions of the authors of 
this meta-analysis was that, ‘Platinum-based adjuvant chemotherapy improved overall 
survival and recurrence-free survival at 5 years in this combined group of patients with 
early stage ovarian cancer defined by the inclusion criteria of the ICON1 and ACTION 
trials’ [18].
Apart from these important large trials, another, albeit smaller, randomized clinical trial 
from Poland was reported [19]. In this study, 150 patients with International Federation 
of Gynaecology and Obstetrics stage Ia, Ib, grade 2–3 and all patients classified as 
Ic and IIa were randomized to either adjuvant radiotherapy or chemotherapy. DFS at 
5-year was 81% (no differences between the two arms).
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OTHER STUDIES IN 2000–2003
The most relevant, non-randomized study in this period was a meta-analysis of 
Scandinavian and other European data in over 1500 patients with stage I ovarian 
carcinoma [20]. The study was done primarily to define prognostic factors for DFS. 
Tumor grade was, once again, identified as the strongest prognostic factor, but capsule 
rupture before and, to a lesser extent, during surgery was also independently related to 
a less-favorable prognosis.
Interestingly, International Federation of Gynaecology and Obstetrics stage Ic and clear 
cell cancer were not by themselves found to be independent prognostic factors. This 
finding confirmed an earlier Italian study in which clear cell cancer in itself also did not 
have an unfavorable prognostic significance, as it was counterbalanced by tumor grade 
[21].
Another (rarely cited) paper related to the long-term risks of chemotherapy for ovarian 
cancer [22]. In this Canadian study of long-term survivors among high-risk early ovarian 
cancer patients, the risk of developing a second primary malignancy was significantly 
increased compared to age-matched controls (relative risk, 1.55 at a median follow-up 
of 13.5 years). These findings are consistent with another retrospective analysis in over 
32,000 patients treated for ovarian cancer [23]. The authors of this study concluded 
that one in every five women would be expected to develop a new malignancy within 20 
years of a diagnosis of ovarian cancer [23].
From these data, it can be said that adjuvant anticancer treatment for malignancies 
with more favorable survival rates should be carefully weighed against the long-term 
risks and side-effects of such therapy.
Faught and co-workers [24] retrospectively emphasized the importance of comprehensive 
surgical staging in early ovarian cancer. Forty-three of 128 women (34%) with presumed 
early ovarian carcinoma were upstaged to stage IIb or III disease. Apart from these 
studies, a number of state-of-the-art studies have been published that merely reflect 
personal interpretations of the literature before the appearance of the large European 
ACTION and ICON1 trials [12,25,26].
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CONCLUSION
The publication of the two largest randomized clinical trials with a no-treatment 
arm following surgery for early ovarian cancer is undoubtedly the most important 
contribution to recent literature on this disease. Any conclusions as to the current state 
of the art should, therefore, seek to clarify the results of these two trials and analyze their 
similarities and differences. On first impression there seem to be more differences than 
similarities between the two trials. One (ICON1) [17] advocates adjuvant chemotherapy 
in (all) patients with early ovarian cancer. The other (ACTION) [16] suggests that 
adjuvant chemotherapy does not work in optimally staged patients. However, there is a 
plausible explanation for this difference and the key features seem to be the composition 
of the study populations and the completeness of the surgical staging. 
From the ACTION trial, we know exactly which portion of patients had been optimally 
staged and which portion had not. The non-optimally staged patients can be regarded 
as harboring occult residual disease in over 25% of cases. This figure might easily 
explain the significant advantage, in terms of overall survival and DFS, of adjuvant 
chemotherapy over observation in these patients. On the other hand, no advantage, in 
terms of overall survival and DFS, of adjuvant chemotherapy could be demonstrated in 
the optimally staged patients.
Of the ACTION trial population, 297 patients (66%) can be considered to have a 25% 
chance of tumor deposits in the abdomen that remained unnoticed due to nonoptimal 
staging. Thus, 74 patients (0.25 x 297), that is 17% of the total ACTION population, 
might represent stage III disease rather than early ovarian carcinoma. This portion of 
unappreciated stage III patients probably accounts for the significant improvement in 
DFS but not in overall survival.
We have no information on the staging performance for the ICON1 trial, but we do 
know that no specific recommendations were given or precautions taken to guarantee 
optimal staging. Considering the disappointingly low yield of optimal surgical staging in 
the ACTION trial, it is realistic to conclude that optimal staging in ICON1 would have 
occurred in far fewer than one-third of the patients. This assumption is supported by 
preliminary results from the Scottish Randomized Trial in Ovarian Cancer [27] showing 
that pelvic and peri-aortic lymph node sampling in early ovarian cancer is hardly ever 
performed in oncology centers in the UK.
Furthermore, comparison of the observation arm of all ICON1 patients on the one hand 
with the two-thirds of non-optimally staged ACTION patients on the other produced 
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identical curves for overall survival [28]. The similarity of these Kaplan–Meier curves 
was all the more striking in view of the fact that ICON1 harbored low-risk patients 
(stage Ia or Ib, grade 1) in 15% of cases, unlike the ACTION trial. This all leads to the 
conclusion that the vast majority of patients in the ICON1 trial should be considered 
as non-optimally staged.
By accepting this assumption it makes it easier to explain the benefits of adjuvant 
chemotherapy in terms of DFS and overall survival. To take this one step further, 
assuming that only a few ICON1 patients and only one-third of the ACTION patients 
were optimally staged, it is likely that not much more than one-sixth of the patients 
in the combined ACTICON population were optimally staged. This means that, by 
and large, 20%, or one out of every five patients, of the ACTION study group would 
have harbored residual tumor tissue following surgery. That figure explains the overall 
survival and DFS advantages of adjuvant chemotherapy in this group.
In conclusion, the ACTION and ICON1 trials have proved, beyond doubt, that adjuvant 
chemotherapy is effective for treating residual tumor deposits in supposed early ovarian 
cancer following non-optimal surgical staging. In this respect, chemotherapy serves to 
correct poor surgery. For optimally staged patients, the ACTION trial suggests that 
adjuvant chemotherapy is of little or no benefit. Withholding chemotherapy in these 
cases might be even more relevant in view of the reported superiority of tumor response 
to chemotherapy in chemo-naive patients [2] and the relatively high risk of second 
primary tumors in long-term survivors of early ovarian cancer.
RECOMMENDATIONS FOR TREATMENT
On the basis of the results of recent randomized trials in early ovarian cancer, a 
comprehensive and complete surgical staging should be pursued. This will diminish or
exclude the risk of unnoticed residual disease, and, therefore, improve the prognosis of 
early-stage ovarian cancer. Achieving the goal of optimal surgical staging at the time of 
the first laparotomy often proves difficult in routine clinical practice. Patterns of care 
for this disease might be redefined as recently suggested by British investigators [29]. 
Policies for referral to oncology centers and the availability of consulting gynecological 
oncologists to perform staging procedures in community hospitals should be evaluated 
in this respect. Incompletely staged patients should be restaged unless physical or 
psychological factors indicate otherwise, in which case adjuvant chemotherapy should 
be given as it has proven effectiveness against residual tumor deposits. The number of 
courses is debatable. The ACTION and ICON1 trials recommended six courses. This 
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number of courses seems the most logical since it is regarded as standard treatment for 
stage III ovarian cancer, and the risk of insufficiently treated stage III disease is the main 
reason for administering adjuvant chemotherapy.
What about giving adjuvant chemotherapy in optimally staged patients? The subgroup 
analysis of the ACTION trial strongly suggests that this does not improve overall survival 
and DFS and would, therefore, do more harm than good. Because this is the first 
time that this has been demonstrated, some practitioners will stick to the old policy 
of treating high-risk, early-stage ovarian cancer with adjuvant chemotherapy. There 
are several reasons why practitioners might resist changes to the standard treatment 
pattern: some might not be convinced by a single randomized trial; some might fear 
withholding a seemingly beneficial therapy to the patient; some might fear medico-legal 
complications in cases of tumor recurrence; and some might be unwilling to refuse the 
patient’s demands to ‘do everything that is possible’.
Nevertheless, advocates of the adjuvant chemotherapy policy should consider the 
harmful effect of unnecessary chemotherapy in terms of morbidity, costs, and impaired 
quality of life. Furthermore, the higher tumor response of recurrences in chemo-naive 
patients and the longterm risks of second primary tumors in survivors of ovarian cancer 
deserve consideration. Finally, it should be realized that in virtually all studies reporting 
risk factors and defining categories of high-risk patients, chemotherapy was given and 
this treatment did not diminish the high-risk status of these patients in any way.
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ABSTRACT
Background: An analysis was performed comparing survival of patients with clear 
cell carcinoma (CCC) to patients with serous adenocarcinoma (SAC) in early ovarian 
cancer. Furthermore, a literature search was done in order to clarify the clinical and 
histopathological features of clear cell tumors of the ovary.
Methods: Between November 1990 and March 2000, 448 patients with ovarian cancer 
FIGO stages I-IIa were enrolled in the EORTC ACTION trial, a randomized study 
comparing adjuvant chemotherapy to observation after surgical treatment in patients 
with early ovarian cancer. Patients in the chemotherapy group received platinum-based 
chemotherapy for at least 4 courses.
Results: 63 patients with clear cell carcinoma (14.1%) were compared to 156 patients 
with serous tumors (34.8%). The median age was 54 years in the CCC group and 56 
years in the SAC group. The treatment arms were well balanced between both groups. 
A significant difference was found in the FIGO stage Ic with capsule rupture, 28/63 
(44.4%) in the CCC patients and 29/156 (18.6%) in the SAC patients ( P < 0.001). 
Recurrences occured in 25% of the patients and this was similar between the CCC 
group and the SAC group. No significant difference was found in overall survival (OS) 
between patients with clear cell carcinoma and serous carcinoma in both treatment 
arms together. In the observation arm the 5-year disease-free survival (DFS) was 71% 
in the CCC group versus 61% in the SAC group, whereas in the chemotherapy arm the 
5-year DFS was higher in the SAC group compared to the CCC group (78% versus 60%). 
Both differences were not statistically significant. 
Conclusions: The present study showed no worse prognosis in patients with clear cell 
carcinoma as compared to patients with serous carcinoma in early ovarian cancer. 
Poorer overall survival in the CCC group receiving adjuvant chemotherapy in relation 
to the SAC group might be explained by possible chemoresistance of clear cell tumors. 
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INTRODUCTION
Clear cell carcinoma (CCC) of the ovary is generally considered to be a tumor with 
poor prognosis and distinct clinical characteristics compared to other epithelial ovarian 
cancers [1]. It is often associated with endometriosis and nulliparity is frequently 
described [2,3]. The incidence of CCC various from 4 to 12% of all ovarian cancers. 
These tumors were first described by Pelham in 1899 as hypernephroma of the ovary 
in view of their resemblance to renal cell carcinoma. Later, terms as mesonephromas 
[4] and hypernephroid carcinoma of the ovary were used. In 1944, Saphir and Lackner 
[5] were the first authors who suggested the term clear cell adenocarcinoma. Different 
hypotheses were made indicating these tumors to be from germ cell origin of the 
endodermal sinus and those who refuted this theory suggested a Müllerian origin. The 
latter is now generally accepted as the nature of this tumor. Histopathologic findings 
of CCC consist of four cell types, typical clear or hobnail, eosinophilic and flattened 
cells in a papillary, solid, or tubulocystic architectural pattern. Since the World Health 
Organization in 1973 defined CCC as a separate histologic cell type [6] a number of 
studies have been performed to clarify the behaviour of this tumor. Several studies have 
shown a high incidence of FIGO stage I tumors [7-13], poorer prognosis compared 
to serous adenocarcinomas of the ovary [10,14,15] and resistance to platinum-based 
chemotherapy [1,13,16]. Most of these trials are retrospective cohort studies and often 
lack a sufficient number of patients.
The purpose of the current study was to compare clinical characteristics, response to 
platinum-based chemotherapy and survival of patients with clear cell carcinoma (CCC) 
versus serous adenocarcinoma (SAC) randomized in a large multicenter trial of early 
ovarian cancer. 
PATIENTS AND METHODS
Between November 1990 and March 2000, 448 patients were entered in the EORTC 
ACTION trial, a randomized clinical study on the role of platinum containing adjuvant 
chemotherapy in early ovarian cancer FIGO stages Ia and Ib (grade II-III), stages Ic and 
IIa (grade I-III) and all stages I-IIa clear cell epithelial cancer of the ovary. Randomization 
between platinum containing chemotherapy and no adjuvant treatment was performed 
after surgical treatment consisting of total abdominal hysterectomy and bilateral 
salping-oophorectomy (TAH plus BSO) and staging. Patients randomized to receive 
chemotherapy were treated within six weeks after surgery for at least four consecutive 
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courses. In the observation arm no further treatment was given until a histologically 
or cytologically proven relapse. The same regimen of chemotherapy according to the 
institution had to be given in case of recurrent disease in the observation arm as in 
the adjuvant chemotherapy group. Analysis of the results was on an intention-to-treat 
basis. A detailed description of the design of the ACTION trial is given in three recently 
published papers by Trimbos et al. [17,18,19].
Analysis
Overall survival and disease-free survival times were defined as the period between 
randomization and death or relapse. Disease-free and overall survival curves were 
generated using the method of Kaplan-Meier [20]. Comparisons of the survival 
distributions were made with the log-rank test. The chi-square or Fisher’s exact test were 
used to evaluate differences in proportions. The Statistical Package for Social Science 
(SPSS) was used for statistical analysis. Significance was defined as a P-value < 0.05.
Furthermore a review of the literature was done in order to evaluate the prognosis 
of clear cell carcinoma in early ovarian cancer. Papers were selected from journals in 
English language literature by a Pubmed search over the last thirty years. Only studies 
which met the following criteria were included:
1) patients with FIGO stage I-II epithelial ovarian carcinoma
2) a minimum of 10 patients with clear cell early ovarian carcinoma in the study group
3) a registrered median survival or a survival curve in the final publication
RESULTS
Of the 448 patients included in the ACTION trial, 156 (34.8 %) were serous 
adenocarcinomas (SAC) and 63 (14.4%) were clear cell carcinomas (CCC). The median 
follow-up period was 5.1 years. Table 1 shows the clinical characteristics of the 219 
patients from both the SAC and CCC group. There was a significant difference in FIGO 
stage (P < 0.001), 44.4% of the CCC were FIGO stage Ic because of capsule rupture 
and this was the case in 18.6% in the SAC group. The time of capsule rupturing was the 
same in both groups, in 24 patients (85.7%) during surgery in the CCC group versus in 
26 patients (89.6%) in the SAC group. Tumors were limited to one ovary (Stage Ia) in 
36.5% (23/63) of the CCC cases and 33.3% (52/156) of the SAC patients. Only 1 patient 
(1.6%) in the CCC group had a tumor extending to both ovaries (Stage Ib) compared to 
15 patients (9.6%) in the SAC group and 2 patients (3.2%) had pelvic extension (Stage 
II) of the CCC cases versus 15 (9.6%) in the SAC patients. Differentation grade was 
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also significantly different in both groups (P < 0.001), 33 of the 63 CCC were poorly 
differentiated (52.4%) against 49 of the 156 in the SAC group (31.4%). No differences 
were noted between CCC and SAC patients for the variables age, pre-treatment CA 125 
values and site of progression. The treatment arms were well balanced between the two 
groups. 
During the follow-up period 56 relapses were found, 16 (25.4%) in the CCC group and 
40 (25.6%) in the SAC group. In both groups together 47 patients died, 16 of the deaths 
occurred in the CCC group, the other 31 in the SAC patients.
Table 1. Patient Characteristics 
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Overall survival rate for the SAC group and the CCC group was not significantly different 
(Figure 1; P = 0.2). The overall survival (OS) by treatment arm is shown in Figure 2 
and 3 (P = 0.8 and P = 0.04 respectively). In the observation arm the OS showed no 
difference between the CCC patients and the SAC patients. In the chemotherapy arm 
however a significant difference in OS between the CCC and SAC group was found. 
Figure 4 shows the DFS in both groups (P = 0.9). The 5-year disease-free survival in 
the chemotherapy arm of patients with serous adenocarcinoma was 78% versus 60% 
for patients with clear cell carcinoma (Figure 5; P = 0.1), whereas in the observation 
arm the 5-year disease-free survival was higher in the CCC group compared to the SAC 
group (71% versus 61%: Figure 6; P = 0.2). The DFS curve of the CCC patients was 
higher in the observation arm and lower in the chemotherapy arm compared to the 
SAC patients. Adjuvant chemotherapy significantly improved DFS in patients with serous 
adenocarcinoma (Figure 7; P = 0.01). In clear cell carcinoma patients no difference in 
DFS was found between the observation arm and chemotherapy arm (Figure 8; P = 0.4). 
The sixteen papers meeting the criteria of the Pubmed search, are summarized in Table 
2. The 5-year survival of patients with FIGO stage I clear cell ovarian carcinoma ranged 
from 49-93% and from 29-88.9% for those patients with FIGO stage II clear cell ovarian 
cancer. The 5-year survival for stage I and II clear cell carcinoma was significantly 
different, 74.1% versus 49.4%, respectively. In Table 3 the survival figures are shown for 
patients with serous early ovarian carcinoma from different studies, resulting in a 5-year 
survival of 76.6% (range 67%-87%) for FIGO stage I patients and 73.5% (range 68-80%) 
for FIGO stage II serous tumors.
Figure 1. Kaplan-Meier curves for OS 
in patients with early ovarian cancer. 
Patients with clear cell carcinoma (n = 
63) and patients with serous carcinoma 
(n = 156).

























































Figure 2. Kaplan-Meier curves for OS 
in patients with early ovarian cancer. 
Patients in the observation arm with 
clear cell carcinoma (n = 26) and patients 
with serous carcinoma (n = 74). Patients 
in the observation were observed until 
adjuvant chemotherapy was indicated.
P = 0.8 using the log-rank test.
Figure 3. Kaplan-Meier curves for OS 
in patients with early ovarian cancer. 
Patients in the chemotherapy arm with 
clear cell carcinoma (n = 37) and patients 
with serous carcinoma (n = 82). Patients 
in the chemotherapy arm received 
immediate adjuvant chemotherapy.
P = 0.04 using the log-rank test.
Figure 4. Kaplan-Meier curves for DFS 
in patients with early ovarian cancer. 
Patients with clear cell carcinoma (n = 
63) and patients with serous carcinoma 
(n = 156).
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Figure 5. Kaplan-Meier curves for DFS 
in patients with early ovarian cancer. 
Patients in the chemotherapy arm with 
clear cell carcinoma (n = 37) and patients 
with serous carcinoma (n = 82). Patients 
in the chemotherapy arm received 
immediate adjuvant chemotherapy. 
P = 0.1 using the log-rank test.
Figure 6. Kaplan-Meier curves for DFS 
in patients with early ovarian cancer. 
Patients in the observation arm with 
clear cell carcinoma (n = 26) and patients 
with serous carcinoma (n = 74). Patients 
in the observation were observed until 
adjuvant chemotherapy was indicated.
P = 0.2 using the log-rank test.
Figure 7. Kaplan-Meier curves for DFS 
in patients with early ovarian cancer. 
Patients with serous carcinoma in the 
chemotherapy arm (n = 82) and patients 
in the observation arm (n = 74). Patients 
in the chemotherapy arm received 
immediate adjuvant chemotherapy and 
patients in the observation arm were 
observed until adjuvant chemotherapy 
was indicated. 
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Figure 8. Kaplan-Meier curves for DFS 
in patients with early ovarian cancer. 
Patients with clear cell carcinoma in the 
chemotherapy arm (n = 37) and patients 
in the observation arm (n = 26). Patients 
in the chemotherapy arm received 
immediate adjuvant chemotherapy and 
patients in the observation arm were 
observed until adjuvant chemotherapy 
was indicated.
P = 0.4 using the log-rank test.
Table 2. Survival rate for Clear Cell Adenocarcinoma of the Ovary
Clear cell
 5-year survival
Author Number of patients FIGO stage I FIGO stage II
Czernobilsky et al. 1970 [2] ? (<12) 80% na*
Aure et al. 1971 [13] ? (<59) 72% na
Norris et al. 1971 [36] ? (<40) 61% na
Shevschuk et al. 1981 [25] ? (<21) 87% na
Brescia et al. 1989 [14] 15 93% na
Crozier et al. 1989 [10] 38 49% 60%
Jenison et al. 1989 [7] 29 50% 29%
Kennedy et al. 1989 [6] 15 68% 42%
Montag et al. 1989 [1] 29 55% 29%
O’Brien et al. 1993 [9] 55 65% 40%
Ahmed et al. 1996 [35] 25 90.2% na
Recio et al. 1996 [37] 37 67% 46%
Behbakht et al. 1998 [11] 27 85% na
Kita et al. 2000 [12] 28 86% 60%
Sugiyama et al. 2000 [38] 59 80% 88.9%
Vergote et al. 2001 [34] 185 72.7% na
Present series 63 63% na
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DISCUSSION
The results from this trial are based on one of the largest series in early ovarian cancer 
patients FIGO stage I-II. Most of the previous studies were retrospective with a small 
number of patients and often too few events to draw valid conclusions.
Clinical features
The clinical characteristics of clear cell carcinoma (CCC) have been widely explored. 
The age distribution, median 55 years, of the patients in the present study is similar 
to that reported by other groups. Nulliparity of greater than 50% has been reported 
in all series of clear cell carcinoma with the exception of those by Doshi and Fine (17 
and 45% respectively) [21,22]. The frequency of concurrent endometriosis in published 
series of clear cell carcinoma varies from 8-55% compared to less than 5% in serous 
ovarian carcinoma [13,14,23]. Many authors described that the presence or absence 
of endometriosis did not appear to affect overall or progression-free survival [11,12].
Many investigators have stated that the percentage of patients with stage I-II disease in 
CCC is significantly higher compared with SAC patients, ranging from 53-66% in patients 
with CCC [7-13]. In a study of clear cell tumors versus matched controls consisting of 
serous ovarian tumors, 66% of the clear cell tumors were early-stage compared to 40% 
of the serous tumors [8]. One of the reasons for more stage I disease in the CCC patients 
may be a higher frequency of symptoms and signs at presentation resulting in earlier 
detection. In the literature no studies reported a primary peritoneal variant of the clear 
cell tumor, while mucinous and serous primary peritoneal cancers have been described. 
Table 3. Survival rate for Serous Adenocarcinoma of the Ovary
Serous
 5-year survival
Author Number of patients FIGO stage I FIGO stage II
Aure et al. 1971 [13] ? 67% na*
Swenerton et al. 1985 [39] 76 70% na
Jenison et al. 1989 [7] 22 87% 80% 
Sugiyama et al. 2000 [38] 52 86% 72.7%
Vergote et al. 2001 [34] 430 75.9% na
Present series 156 74% 68%
Total 706 76.6% 73.5%        
*na: not applicable
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Another argument for the fact that clear cell tumors stay localized until they become a 
pelvic cyst is the finding in a study of Okhawa et al. [24] that clear cell tumors remain 
attached to the mesothelial layer while serous tumors invade rapidly into this cell layer. 
Only 2 patients (3.2%) in our study group of CCC had pelvic extension, while 15/156 
(9.6%) in the SAC group had FIGO stage IIa. It is also unusual to encounter bilateral 
involvement among stage I ovarian clear cell carcinoma patients. In the literature only 
4.2% of stage I patients have been noted to have bilateral involvement and we observed 
this in 1 of the 63 patients (1.6%) in the CCC group versus 15 (9.6%) in the SAC group.
In the current study almost half of the patients in the CCC group had FIGO stage Ic, with 
44.4% capsule rupture versus 18.6% in the SAC group. A possible explanation for this 
biologic phenomenon might be a larger tumor size of CCC as described in many series 
[7,12,13,24,25], and therefore more often capsule rupture before or during surgery.
In our study no difference was found in DFS and OS between the CCC and SAC group 
although almost half of the patient in the CCC group had FIGO stage Ic because of 
capsule rupturing compared to 18.6% in the SAC group. 
Grading
One of the difficulties of managing clear cell carcinomas is the histologic grading. 
Different grading systems are used for ovarian cancer. The FIGO grading system [26] 
is primarily based on architectural features like the GOG grading system [27] which 
also in a lesser extent considers nuclear features, but varies on the histologic type being 
graded. Both grading systems cannot be used for clear cell carcinoma of the ovary. 
The WHO grading system [6] is dependent on observer’s impressions derived possibly 
from both architectural and nuclear features, but not defined in a quantitative manner. 
Silverberg [28] proposed a universal grading system for all invasive ovarian carcinomas, 
based on the Nottingham system for grading all types of mammary carcinoma. Using 
this system tumors are graded architecturally as grade I-III according the (predominant) 
architectural pattern (glandular, papillary, solid), nuclear as grade I-III (slight, moderate, 
marked) and also on mitotic index. The efficacy of this grading system was tested in 
different series and seems to be valuable in predicting survival. They also found that 
histopathologic typing in ovarian cancer was less of prognostic significance for survival 
compared to grading, but better at predicting tumor responsiveness to chemotherapy. 
Ovarian clear cell cancer can be adequately graded by the Silverberg system.
Chemoresistance
In our study 16/63 (25.4%) recurrences were found in the CCC group and a similar 
percentage was found in the SAC group 40/156 (25.6%), with a median time to 
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recurrence of 28 months. Reviewing the literature, different numbers of recurrences 
are described. In a series of Bekbakht et al. [12], 10/27 (37%) patients with stage I 
clear cell carcinoma who received adjuvant platinum-based chemotherapy relapsed 
from which 7/13 (54%) were stage Ic tumors. In comparison, Hreshchyshyn et al. [29] 
reported a 6% recurrence rate in patients with stage I epithelial ovarian cancer treated 
with postoperative chemotherapy. The high relapse rate in clear cell carcinoma may 
be related to chemoresistance. In support of this concept, clear cell carcinoma cell 
lines were found to exhibit resistance to cisplatin in cell culture [16]. In a study of Kita 
et al. [13] 5 of the 10 patients with stage II disease had macroscopic residual disease 
from which 60% died within 9 months after initial surgery and adjuvant cisplatin based 
chemotherapy, also suggesting chemoresistance. In order to clarify the underlying 
mechanism of cisplatin resistance in clear cell carcinoma Itamochi [30] conducted a 
study in 11 CCC and 5 SAC cell lines. They found that the doubling time for CCC cells 
was significantly longer than that for SAC cell lines (61.4 vs 29.8 hour), suggesting 
that the resistance of CCC to cisplatin may be caused by low cell proliferation. In our 
study the disease-free survival (DFS) showed an advantage in the observation arm in 
the CCC group, while in the chemotherapy arm the DFS was higher in the SAC group. 
Both differences were not statistically significant but showed a trend and could be 
partly explained by a possible chemoresistance of the clear cell tumors. A significant 
difference was found in the SAC group in favor of the adjuvant chemotherapy arm while 
in the CCC group no survival difference was shown between the observation arm and 
chemotherapy arm. 
Prognosis
Regardless of the high recurrence rate for clear cell carcinoma , overall survival is not 
significant lower than the survival of patients with serous ovarian cancer in the present 
study. In the current study, more patients in the CCC group were optimally staged 
(39.7%) versus the SAC group (28.8%). Therefore, we performed a separate analysis for 
only the optimally staged patients. Even if we look at the optimally staged CCC and SAC 
patients the outcome was the same, no significant difference could be found in DFS (P 
= 0.76) and OS (P = 0.28). Furthermore, the survival benefit in the chemotherapy arm 
of the SAC group compared to the CCC group disappeared (P = 0.11). Five-year survival 
rates in stage I-II clear cell carcinoma varied from 50-73% in reported series. Many 
studies were conducted on histologic type as prognostic factor. A number of studies 
gave patients with clear cell carcinoma of the ovary favorable prognosis compared 
to serous carcinoma of the ovary [10,14,15]. On the other hand, a same amount of 
studies regarded clear cell carcinoma as having a worse prognosis than other epithelial 
cancers [8,31,32]. Jenison et al. [8] noted that 22 patients with stage I clear cell ovarian 
carcinoma demonstrated a significantly worse estimated 5-year survival than did 11 
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patients with serous carcinoma (50% vs 87%, P < 0.001). Most of the studies however 
showed no difference in survival for patients with clear cell ovarian cancer compared to 
other histologic types of ovarian cancer. Our study also lends support to the postulation 
that clear cell carcinoma has a relatively good prognosis. Zanetta [33] analysed 351 
patients with stage I ovarian cancer and could not find a significant difference in DFS 
and OS comparing clear cell tumors versus other histologic cell types. In a recent study 
of Vergote et al. [34] on 1545 FIGO stage I ovarian cancer patients histologic type was 
not of prognostic value, observing a 5-year survival of 72.7% in clear cell carcinoma 
patients versus 75.9% in patients with serous adenocarcinoma. In the multivariate 
analyses the degree of differentation was identified as the most powerful prognostic 
indicator but in this study clear cell carcinoma were not graded [34].
We conclude that although clear cell ovarian carcinomas do have unique clinical 
features, they have similar prognosis compared to serous ovarian cancer in early stages. 
The role of chemoresistance needs further study in these type of tumors.
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ABSTRACT
Background: Early ovarian cancer patients are often incompletely staged during initial 
surgery [1–3]. This omission can have serious adverse consequences for the prognosis of 
patients as the completeness of surgical staging has been identified as an independent 
prognostic parameter for survival [4,5]. The reasons for the problem of inadequate 
staging of early ovarian cancer are largely unknown. We have analysed the data of a 
large randomized trial in early ovarian cancer in which detailed information of the 
surgical staging procedure was monitored [5].
Methods: Data of the EORTC Adjuvant ChemoTherapy in Ovarian Neoplasm 
(ACTION) trial were used in which 448 early ovarian cancer patients were randomized 
between postoperative chemotherapy in one arm and observation following surgery 
in the other. In this trial strict criteria for surgical staging were advised but optimal, 
complete staging was performed in only 1/3 of patients. Staging characteristics of the 
incompletely staged patients were analysed and factors that could explain the failure to 
perform a complete staging were studied.
Results: Sampling of para-aortic nodes was omitted in 78% of the incompletely staged
patients, while 52% of these patients had no pelvic lymph node dissection. Taking blind 
biopsies from different peritoneal sites was not performed in more than 1/3 of the 
incompletely staged group. Omission of the staging steps ranged from 3% (infracolic 
omentectomy) to 55% (biopsy of the right hemi-diaphragm). A significant difference (P = 
0.04) between the fraction of completely staged patients was found when comparing 
institutes who entered less than 5 patients (21%) versus those who included more than 
20 patients (37%) in the trial.
Conclusions: Even in a randomized trial in which comprehensive surgical staging was
strongly advised in the study protocol the majority of patients (66%) were incompletely
staged. Factors relating to a lack of surgical skills attributed most to the number of 
incompletely staged patients, but insufficient knowledge of the tumor behaviour and 
routes of spread of ovarian cancer also contributed substantially to this problem. 
Multicenter trials recruiting patients from many institutes with small volume contribution 
to the study, run the risk of inadequate adherence to the study protocol.
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INTRODUCTION
Ovarian cancer carries a dismal prognosis [6] and almost the only chance of long-
term survival is related to early detection of the disease and a flawless and adequate 
management of the early stages of this ‘silent killer’[7]. An important initial step of 
such adequate management is a thorough, comprehensive surgical staging procedure 
[1,4,5,8]. Only the most accurate determination of the extent of the disease will enable 
the definition of subsets of patients requiring adjuvant therapy and those in whom 
adjuvant treatment can be considered overtreatment.
Consequently, lack of proper staging was found to be an independent prognostic factor 
in several series [4,5]. In the ACTION trial the optimally staged patients did not benefit
from adjuvant chemotherapy [5]. Incomplete surgical staging at initial surgery has been 
reported between 32% and 72% of cases in different studies [2,9,10]. Knowledge of 
the reasons for the wide spread inadequacy of staging early ovarian cancer is lacking. 
Only a few studies have addressed this issue [3,9,11] and that is unfortunate, because 
a change in this aspect of oncology care can only be hoped for if this deficiency can be 
sufficiently explained.
The EORTC ACTION trial was one of the largest randomized clinical trials in early 
ovarian cancer undertaken so far [5]. In this study patients were randomized between 
observation following surgical treatment and adjuvant platin-based chemotherapy. 
Detailed information about the staging procedure was available for every patient. These 
data and other characteristics that might relate to the completeness of surgical staging 
were analysed.
The aim of the study was to shed more light to the understanding of the reasons for 
failure of adequate staging surgery in early ovarian cancer.
PATIENTS AND METHODS
Between November 1990 and March 2000 448 patients were enrolled in the EORTC 
ACTION trial, a randomized clinical trial to study the significance of platinum-based 
adjuvant chemotherapy in early ovarian cancer. Detailed information of all patients 
on the staging performance was available and these data were analysed in the present 
study. Patients were divided in a completely staged group and in an incompletely 
staged group. If all the staging steps mentioned in Table 1 were completed, staging was 
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considered complete. All other cases were labelled incomplete. The number of patients 
entered by the 40 institutes of the nine participating countries was related to the two 
staging categories.
For the comparison of fractions (complete or incomplete staging) the χ² test was used 
and P-values < 0.05 were considered statistically significant.
Table 1. Staging steps necessary to arrive at a complete surgical staging procedure for early ovarian cancer 
following bilateral salpingo-oophorectomy and total abdominal hysterectomy*
Staging guidelines
Inspection and palpation of all peritoneal surfaces
Biopsies of any suspect lesions for metastases
Biopsies or removal of any adhesions surrounding the (area of the) primary tumor
Peritoneal washing
Infracolic omentectomy
(Blind) biopsies of right hemidiaphragm, of right and left paracolic gutter, of pelvic sidewalls, of ovarian 
fossa, of bladder peritoneum, and of cul-de-sac
Iliac and peri-aortic lymph node dissection
* patients with stage Ia disease who wished to preserve fertility were permitted to have only an unilateral salpingo-
oophorectomy
RESULTS
Clinical and tumor characteristics of the completely and incompletely staged patients are 
given in Table 2. No differences in mean age, histologic cell type or grade of differentiation 
of the tumors were seen. In the incompletely staged group the omitted staging steps were 
divided into two categories: one group of procedures carrying an appreciable risk of 
surgical morbidity [11] and for which additional surgical skills have to be present and 
another group of procedures not requiring specific surgical abilities and in which virtually 
no surgical morbidity was involved. These two groups are shown in Table 3. The surgical 
morbidity group contributed most to the amount of neglected staging steps.
In 78% of incompletely staged patients para-aortic lymph node sampling was not 
performed followed by 55% omitted biopsies of the right hemi-diaphragm and 52% 
pelvic lymph node sampling. However, the low morbidity group did also contribute to 
the total of complete surgical procedures: blind biopsies of paracolic gutters of 39% 
and blind biopsies of pelvic side wall also of 39%. Even a totally harmless procedure as 
taking peritoneal washings for cytology was omitted in 33 of 295 incompletely staged 
patients (11%); Table 3.
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Age 56 54 0.73
FIGO stage
Ia 46 (30,5%) 109 (36,9%)
Ib 13 (8.6%)  24 (8.1%)
Ic ovarian surface 24 (15.9%)  26 (8.8%) 0.29
Ic capsule rupture 38 (25.2%)  78 (26.5%)
Ic ascites/malignant washing 18 (11.9%)  39 (13.2%)
IIa 12 (7.9%)  19 (6.5%)
Histologic type
Serous 45 (29.8%) 111 (37.6%)
Mucinous 29 (19.2%)  48 (16.3%)
Endometrioid 44 (29.1%)  76 (25.8%)
Clear cell 25 (16.6%)  38 (12.9%) 0.65
Undifferentiated  3 (2.0%)   5 (1.7%)
Other  2 (1.3%)  14 (4.7%)
Missing  3 (2.0%)   3 (1.0%)
Differentiation grade
Well 15 (9.9%)  39 (13.2%)
Moderetely 87 (57.6%) 141 (47.8%) 0.30
Poorly 47 (31.1%) 109 (37.0%)
Unknown  2 (1.3%)   6 (2.0%)
*Surgical staging performance was missing in 2 patients
Table 3. Omitted staging steps in early ovarian cancer patients
Procedure not performed
number of 295 incompletely 
staged patients   %
Procedure difficult or associated with increased morbidity
Biopsy of right diaphragm 161 55
Sampling para-aortic lymph nodes 230 78
Sampling of pelvic lymph nodes 153 52
Lymph nodes
Infracolic omentectomy   10   3
Easy procedure; no morbidity involved
Biopsies of paracolic gutters 114 39
Biopsies of side wall 116 39
Peritoneal washing   33 11
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The staging categories of the different institutions divided by the number of patients 
randomized in the trial are listed in Table 4. In total 40 European institutions from 9 
countries were enrolled in the ACTION trial. From these 40 centers, 19 centers entered 
less than five patients, 7 centers between 6 and 10 patients, also 7 centers between 11 
and 20 patients and the other 7 centers more than 20 patients. 
Table 4. Staging category by number of patients randomized per center






 0 – 5 19  20.5%  79.5%
 6 – 10  7  25.9%  74.1%
11 – 20  7  36.8%  63.2%
> 20  7  36.5%  63.5%
A significant difference was found between the number of patients who were completely 
staged in the centers which entered a small number of patients (1–5 patients) compared
to the centers which entered a large number of patients (>20: 20.5% and 36.5%, 
respectively, P = 0.04). Also a significant difference was shown in the percentage of 
completely staged patients dividing the centres into two groups (1–10 patients: 23.2% 
and >10 patients: 36.7%, P = 0.01). Tables 5 and 6 show the number of patients in 
whom blind biopsies were taken and para-aortic and pelvic lymph node sampling was 
performed by the four European countries which entered most of the patients in the 
trial. Pelvic lymph node sampling was carried out in 78% of the patients in Spain while 
Table 5. Blind biopsies by country of randomization
                                                                                            Blind biopsies performed
Country
Number of patients 
randomized Side wall Paracolic gutters
Right  
hemidiaphragm
Italy 311 241 (77.5%) 224 (72%) 179 (57.7%)
Spain  51  40 (78.4%)  27 (52.9%)  35 (68.6%)
The Netherlands  43  28 (65.1%)  36 (83.7%)  32 (74.4%)
Portugal  13  12 (92.3%)  13 (100%)   7 (53.8%)
 Understanding the problem of inadequately staging early ovarian 87
5
these percentages were 66%, 44% and only 8% for Italy, the Netherlands and Portugal, 
respectively. On the other hand, para-aortic lymph node sampling was performed in 
55% of the patients in Italy and the Netherlands while 42% of the patients in Spain and 
7% in Portugal had a para-aortic lymph node sampling. Biopsy of the right diaphragm 
was mostly taken in the Netherlands (74%) compared to 69% in Spain, 58% in Italy and 
54% in Portugal. Most of the biopsies from the paracolic gutters and peritoneal side 
wall were taken in Portugal in 100% and 92% of the patients, respectively.
DISCUSSION
In the daily life practice the performance of a complete, comprehensive staging 
procedure in early ovarian cancer seems to be difficult to accomplish in all patients. In 
the EORTC ACTION trial all the necessary staging steps to achieve a complete staging 
procedure were specifically mentioned in the study protocol and it was strongly advised 
to execute them.
Nevertheless, in 295 of the 448 patients (66%) one or more staging acts had been 
omitted. This is a sobering finding because one of the consequences of clinical trials 
should be that they keep the participating clinician focused on the state-of-the art 
approach of a particular patient group in the study protocol.
Admittedly, the criteria in the ACTION trial to qualify for a complete staging procedure 
were very strictly applied, but a minority of 1/3 of completely staged patients remains a 
disappointingly low figure, and this sheds great doubts on the daily life practice outside 
a trial situation. Furthermore, we know from the results of the ACTION trial published 
Table 6. Lymph node sampling by country of randomization
                                                                                               Lymph node sampling performed
Country
Number of patients 
randomized Pelvic Para-aortic
Italy 311 206 (66%) 130 (41.9%)
Spain  51  40 (78.4%)  28 (54.9%)
The Netherlands  43  19 (44.2%)  24 (55.8%)
Portugal  13   1 (7.7%)   1 (7.7%)
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earlier [5] that only the non-optimally staged patients benefit from adjuvant platin-
based chemotherapy and the optimally staged patients do not need further treatment. 
To do something about this deficiency in patient care requires insight into the reasons 
why comprehensive staging for all patients with early ovarian cancer is so hard to 
achieve.
One of the reasons may be that the first diagnosis or suspicion of early ovarian cancer is 
frequently made during a surgical procedure for an acute abdomen or for symptoms of 
an ovarian cyst and therefore is unexpected. These procedures are normally undertaken 
by general gynecologists without surgical skills to perform a proper staging and without
the necessary knowledge of tumor behaviour and sites at risk for tumor spread.
We have tried to differentiate between a lack of surgical skills (more difficult procedures 
with morbidity involved) and a lack of sufficient knowledge of risk sites for ovarian 
cancer metastases (easy procedures without appreciable morbidity risk). In the former 
category retroperitoneal lymph node retrieval was neglected in 78% and 52% of 
incompletely staged patients. These findings concur with those of a similar study in 
Dutch patients (70%) [11], and those of an earlier study from the United States [9].
In the group of easy procedure the sites most commonly omitted in the present study 
were the paracolic gutters (39%), pelvic side wall peritoneum (39%) and even peritoneal 
washings (11%). In the Dutch study mentioned before, the figures were similar for the 
peritoneal washings (10%) but very different for the paracolic gutters (85–90%) and the 
pelvic side wall (73%) [11].
As it seems that lack of surgical expertise as well as deficient knowledge of ovarian 
cancer spread are responsible for the staging problem at hand, a solution for these 
shortcomings has to be solved rather in the organisation of health care programs and 
subspecialisation of gynecologic oncologists than in the sheer education of general 
gynecologists.
Only a more efficient referral policy could serve to have the surgical staging procedures 
concentrated by gynecologic oncologists with not only the skills and knowledge to do 
it, but also the maintenance of experience to deal with a relatively infrequent condition. 
In this context a policy of only removing a suspicious ovarian cyst or mass and waiting 
for the definite pathology might help to organise the place and the surgeon for a proper 
staging procedure later, more effectively [12-14].
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In the pre-operative evaluation of an adnexal mass, the widely used Risk of Malignancy 
Index (RMI) which is based on menopausal status, ultrasound morphology of adnexal 
masses and absolute level of serum CA-125 may help in differentiating between a 
benign or malignant mass with a sensitivity from 71% to 88% and a specificity ranging 
between 74% and 89% in different studies [15-17]. The results of a multicenter study, 
the International Ovarian Tumor Analysis (IOTA), show that pattern recognition by 
ultrasound correctly classified 93% of the tumors as benign or malignant while serum 
CA-125 correctly classified at best 83% of the masses [18].
The ACTION trial was a multicenter randomized trial and performed by clinical 
research groups consisting of different types of hospitals. We found in this study a clear 
correlation in the number of patients enrolled by the different institutes and the surgical 
staging category. Institutes who entered less than 5 patients performed complete 
staging in 20.5% of the patients, while this percentage increased to almost 37 if more 
than 10 patients per institute were enrolled in the trial. The volume issue is important 
in oncology. In a population-based study of 2450 ovarian cancer patients done by Ioka 
and colleagues, patients receiving care in very low volume hospitals were seen to have 
a 60% higher risk of death than patients receiving care in high volume hospitals (P < 
0.01) [19]. Vernooij and colleagues [20] found that the level of specialisation and the 
volume of the hospital were strongly related to the proportion of adequately staged 
patients and the overall survival was best in patients treated in specialised hospitals and 
by gynecologists who treated a high number of patients.
The conclusion of all this is, that if we allow too many institutes that enroll a low 
number of patients in multicenter clinical studies, we run an increased risk of inadequate 
adherence to the study protocol. We may have to monitor in future trials more carefully 
the violation of the study protocol with quality control during the study. In the case of 
early ovarian cancer this means suboptimal performance to follow the required steps 
of surgical staging.
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ABSTRACT
Background: The purpose of this study was to determine the effect of lymph node 
sampling and taking of blind biopsies as part of the surgical staging procedure for early 
ovarian cancer on disease-free survival (DFS) and overall survival (OS) in patients who 
received no adjuvant chemotherapy. 
Methods: In the EORTC ACTION trial 448 patients with early ovarian carcinoma were 
randomized between November 1990 and March 2000, 224 patients to observation 
and 224 to adjuvant platin-based chemotherapy. Only patients allocated to observation 
were included for the current study. Analyses were performed in a subgroup of 
75 optimally staged patients (group A), 46 patients in whom all staging steps were 
performed except para-aortic or pelvic lymph node sampling (group B) and 14 patients 
who fulfilled all staging criteria but in whom no blind peritoneal biopsies were taken 
(group C). The study group did not differ in stage distribution, cell type or tumor grade.
Results: Significantly improved 5-year DFS (P = 0.03) and 5-year OS (P = 0.01) were 
found in group A (optimally staged) versus group B (no lymph node sampling). A 
significant difference was also shown in 5-year DFS (P = 0.02) and 5-year OS (P = 0.003) 
between group A and group C (no blind biopsies). Recurrences occurred in 11/75 
patients (14.6%) in group A , 16/46 patients (34.8%) in group B and 5/14 (35.7%) in 
group C. The 5-year DFS in group A was 79% versus 61% and 64% in group B and C 
respectively. The 5-year OS decreases from 89% in group A to 71% in group B and 65% 
in group C.
Conclusions: In this study statistically significant differences were found in patients 
in whom para-aortic and pelvic lymph node sampling and taking of blind peritoneal 
biopsies were undertaken compared with patients in whom these staging steps had 
been omitted. These findings support the relevance of lymph node sampling and the 
taking of blind peritoneal biopsies in the surgical staging of early ovarian cancer.
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INTRODUCTION
Early ovarian cancer patients are often surgically understaged. Figures of 33% to 67% of 
patients with inadequate surgical staging have been reported [1,2], depending on the 
definition of optimal staging.
The two staging steps that are most frequently omitted include retroperitoneal lymph 
node dissection and the taking of blind biopsies [3,4]. These omissions take place despite 
the well documented route of metastasis via the peritoneal fluid and the retroperitoneal 
lymph nodes. The Gynecologic Oncology Group (GOG) and the European Organisation 
for Research and Treatment of Cancer (EORTC) has well described guidelines for the 
staging laparotomy of early ovarian cancer patients [5,6]. 
The incidence of lymph node involvement in apparently early ovarian cancer is 
approximately 14% for stage I and 38% for stage II [7-16]. Lymph node metastasis in 
stage I ovarian cancer is mostly found in stage Ic patients, grade 3 tumors and serous 
carcinoma [7-15]. Positive findings of blind biopsies of various peritoneal sites in 
apparently early-stage ovarian cancer has been demonstrated between 3 and 17% of 
the cases [17,18].
Despite the overwhelming evidence of the importance of these two routes of tumor 
spread, the particular staging steps to detect it carry inherent problems in clinical 
practice. The reasons that lymph node dissection and blind biopsies are so often 
neglected have been reported partly because of lack of technical skills and partly 
because of lack of knowledge of early ovarian cancer spread [3].
Contrary to the large number of papers analyzing the incidence of lymph node spread 
or intraperitoneal dissemination of early ovarian cancer, studies on the prognostic 
significance of lymph node removal or taking of blind peritoneal biopsies are scarce [9-
11]. This scarcity is the more problematic because a proven prognostic consequence of 
these staging steps may contribute to a general acceptance of the importance of these 
staging elements.
The current study was undertaken to analyze the prognostic significance of lymph node 
sampling and the taking of blind peritoneal biopsies during surgical staging of early 
ovarian cancer.
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PATIENTS AND METHODS
In the EORTC Adjuvant ChemoTherapy in Ovarian Neoplasm (ACTION) trial 448 
patients were included between November 1990 and January 2000 by 40 centers 
from nine European countries. Patients with FIGO stages Ia-Ib, grade II-III, all 
stages Ic-IIa and all stages I-IIa clear cell carcinoma were eligible for the study. After 
surgical treatment and staging, including total abdominal hysterectomy and bilateral 
salpingo-oophorectomy using a midline incision, patients were randomized between 
an observation arm or adjuvant chemotherapy arm consisting of at least four courses 
of platinum-based chemotherapy. Surgical staging had to consist of at least careful 
inspection and palpation of all peritoneal surfaces, with biopsies of any suspect lesions, 
such as adhesions adjacent to the ovarian tumor. However, far more comprehensive 
staging was strongly advised, including omentectomy, peritoneal washings, blind 
biopsies from the peritoneum in the pelvis (pouch of Douglas, bladder, pelvic sidewalls), 
the paracolic gutters, the right hemidiaphragm and iliac and para-aortic lymph node 
sampling. Only if all staging steps had been performed, the procedure was categorized 
as optimal. For a detailed description of the inclusion criteria of this trial we refer to a 
previous publication [2].
Data from the EORTC ACTION trial were used for the present study. The dataset 
comprises detailed information on staging steps and prognosis. The median follow-up 
duration at the time of analysis was 5.5 years.
SPSS version 15.0 (SPSS inc., Chicago, IL) was used for statistical analysis. Categorical 
variable comparisons were conducted by 2-tailed χ² and Fisher exact tests. Parametric 
comparisons were compared by analysis of variance and Student t test. Survival 
estimates were calculated using the Kaplan-Meier product limit method. Comparisons 
between survival curves were made using the log-rank-test. Two-tailed P values are 
reported, with the a for all tests set at < 0.05 as significant.
RESULTS
From the 448 patients of the ACTION trial, 224 patients were randomized to the 
adjuvant cisplatin-based chemotherapy arm en 224 to the observation arm. For the 
present analysis only patients in the observation arm were included. From the 224 
observation arm patients 75 patients were optimally staged (group A) and from 46 
patients all staging steps were performed except para-aortic or pelvic lymph node 
sampling (group B). Group C consisted of patients in whom the taking of blind biopsies 
was omitted but all other steps were carried out (n=14). The other 89 patients out of 
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the 224 patients in the observation arm were excluded from this analysis because a 
various of different staging steps together were not performed. In the analysed study 
population 95% of the patients had a vertical midline incision and for those were a 
blind biopsy of the right hemidiaphragm was taken 93% of the patient has a vertical 
midline incision. For a description of the prognosis of the different staging categories in 
all patients we refer to a previous publication of  Trimbos et al. [2].
 
Table 1 and 2 show a literature review of lymph node involvement in early ovarian cancer.
Table 3 shows the distribution of clinical and histological characteristics of the three 
groups. No difference between group A and the other two groups in stage distribution, 
histological cell type and differentiation grade could be found.
Figure 1 shows the overall survival (OS) curve of the patients in group A and group B. 
A significantly different overall survival was shown between both groups (P = 0.01) with 
a 5-year overall survival of 89% (group A) versus 71% (group B). During the follow-up 
period 8% of the patients died (6/75) in group A of whom 2 patients of another cause 
of death than ovarian cancer, while 23.9% of the patients (11/46) in group B died of 
the disease. 
Also a significant difference in disease-free survival (P = 0.03) was found between group 
A (optimally staged) and group B (no pelvic or para-aortic lymph node sampling), 
resulting in a 5-year disease-free survival rate of 79% (group A) and 61% (group B), 
figure not shown. In group A, 11 of the 75 patients recurred (14.6%) versus 16 of the 
46 patients (34.8%) in group B. 
Table 1. Lymph node involvement FIGO stage I-II ovarian cancer; a literature review
Authors (ref.)   Number   Stage I        Stage II
Benedetti Panici 1993[7] 37  5/35 (14.2%)   0/2 (0%)
Baoicchi 1998 [8] 18  4/18 (22.2%)
Suzuki 2000 [9] 47  5/47 (10.6%)
Sakuragi 2000 [10] 94  4/78 (5.1%)  5/16 (31.3%)
Cass 2001 [11] 69 14/69 (20.2%)
Morice 2003 [12] 100 17/85 (20%)  6/15 (40%)
Negishi 2004 [13] 150  8/123 (6.5%) 11/27 (40.7%)








(6%)  5/21 (24%)
Total 915 109/797 (13.7%) 45/118 (38.1%)
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Table 2. Lymph node involvement FIGO stage I ovarian cancer by substage, grade and histology; literature review
Stage Grade Histology
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N*: number of patients with positive nodes
Analyzing the DFS (figure not shown) and OS (figure 2) comparison of group A and 
group C, we found a significant difference for DFS (P = 0.02) as well as OS (P = 0.003), 
showing a 5-year DFS of 79% versus 64% respectively and 5-year OS of 89% (group A) 
and 65% (group C). Recurrences occurred in 5/14 (35.7%) of the patients in group C 
versus 11/75 patients (14.6%) in group A. In the patients in whom blind biopsies of the 
peritoneum were not taken (group C) 5 patients (35.7%) died of the disease compared 
to 6/75 (8%) in the optimally staged patients (group A).
The sites of progression were different in the three groups as shown in Table 4. In 
the optimally staged group A, 1/75 (1.3%) patients recurred only in the pelvis, while 
these percentages were 13.1% (6/46) and 14.3% (2/14) for group B (no lymph node 
sampling) and group C (no blind biopsies) respectively. Intraperitoneal progression was 
seen in 5.3% in group A versus 8.7% in group B and 14.3% in group C.
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Figure 2. Kaplan - Meier curves for overall survival in patients with early ovarian cancer in the observation arm 
of the trial. Patients in the optimal group A (n=75) and patients with blind biopsies omitted group C (n=14). 
P = 0.003 using the log-rank test.
Figure 1. Kaplan - Meier curves for overall survival in patients with early ovarian cancer in the observation arm 
of the trial. Patients in the optimal group A (n=75) and patients with no para-aortic or pelvic lymph node 
sampling (LNS) group B (n=46). P = 0.01 using the log-rank test.
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DISCUSSION
Lymph node sampling is one of the cornerstones of the surgical staging in early ovarian 
cancer. Surgical skills are required to carry out a lymph node dissection and the procedure 
is not without risk or side effects. The morbidity described for a lymphadenectomy 
includes lymphocyst, nerve and vessel injury and increased operation time and blood 
loss [3,8].
Performing a lymph node sampling in early ovarian cancer patients can cause problems 
in daily practice. Most of the patients with early ovarian cancer are diagnosed by a 
general gynecologist, sometimes unexpected when the patient is operated for acute 
abdominal pain or a pelvic mass. In this setting the lymph nodes are often not removed 
and the patient is not always restaged thereafter. Where and by whom the patient 
with early ovarian cancer is treated depends on the particular organisation of the 
health care. In the Netherlands there is no referring obligation of patients with early 
ovarian cancer but a gynaecologic oncologist has to be part of the operating team for a 
staging surgery which is not in all cases done. To change a system is difficult and solid 
evidence that centralisation of these patients improves the prognosis, is needed. Studies 
regarding the prognostic value of all staging steps including lymph node dissection and 
taking of blind biopsies should contribute to the general application of these steps in 
the surgical staging of early ovarian cancer patients. In a recent publication Verleye et 
al. [19] proposed EORTC Gynaecologic Cancer Group (GCG) quality indicators for 
staging laparotomy in ovarian cancer grossly confined to the pelvis in order to improve 
the quality of surgery in ovarian carcinoma patients. Kommoss et al. [4] showed that 
the introduction of a quality assurance and management program for treatment of 
early ovarian cancer patients represents a major improvement of patient care.
The impact of lymph node sampling, lymphadenectomy or positive nodes on prognosis 
in early ovarian cancer remains controversial. Baiocchi et al. conducted a multivariate 
analysis and revealed that lymph node status was the most valuable prognostic 
factor in patients with disease limited to the ovary [8]. In a recent randomized study 
in macroscopic early ovarian cancer patients Maggioni et al. [15] performed either a 
systematic pelvic and para-aortic lymphadenectomy (n=138) or a random sampling of 
lymph nodes (n=130). The incidence of positive nodes was significantly higher in the 
lymphadenectomy group than in the sampling group, respectively 22% and 9%, while 
the recurrence rates were 22% versus 30%. No significant difference in 5-year overall 
survival (84.2% versus 81.3%) and 5-year progression-free survival (78.3% versus 71.3%) 
was found between both groups, but this could have been expected as the number of 
patients randomized was too small to detect a significant difference with a reasonable 
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power. Also no difference in the sites of progression was found [15]. In our current 
study, we found in the group of optimally staged patients only one pelvic recurrence 
(1%), while in the group without pelvic and or para-aortic lymph node sampling 13% 
of the patients recurred only in the pelvis. Our study differs from that of Maggioni et al. 
[15] in various aspects. First, our analysis was a subgroup analysis of a randomized trial 
with a study design that was not primarily intended to study the omission of particular 
surgical steps during the staging procedure. Second, Maggioni et al. [15] compared 
restrictive versus extensive lymph node removal whereas the current study compared 
lymph node sampling versus no sampling at all. And third, an unknown percentage of 
patients in Maggioni’s study received postoperative chemotherapy versus no patients in 
the current study. Contrary to Maggioni’s conclusions we found a significant difference 
in DFS as well as OS in favour of completely staged patients in our study. 
The prognostic significance of lymphadenectomy in the staging of early ovarian cancer 
is supported by a large retrospective study of stage I ovarian cancer patients of Chan et 
al. [20]. Lymphadenectomy improved the disease-specific survival of all patients from 
87% to 92.6%. Furthermore, they found that the extent of lymphadenectomy (0 nodes, 
less than 10 nodes, and 10 or more nodes) was a significant prognostic factor for 
improved survival in the multivariable analysis [20].
We are aware of the limitation of our study with small number of patients especially for 
the group of patients without blind biopsies. Therefore, we should be careful to draw 
too strong conclusions, on the other hand all analyses were statistically significant. 
Furthermore these data were derived from a randomized trial and one of the largest 
series of early ovarian cancer patients who were treated in a standardized way with well 
described surgical staging steps.
In our study we have shown that both 5-year DFS and 5-year OS were statistically 
significantly better for optimally staged patients compared to those in whom either 
sampling of lymph nodes or taking of blind biopsies were omitted. The 5-year OS 
decreases from 89% in patients who were optimally staged to 71% when lymph node 
sampling was not performed. Optimal surgery improved survival by correcting false 
stage allocation and upstaging.
In conclusion we demonstrated the importance of lymph node sampling and taking of 
blind peritoneal biopsies in the surgical staging for the prognosis of early ovarian cancer 
patients in this study. 
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ABSTRACT
Objectives: Since the incorporation of capsule rupturing and other prognostic variables 
in the FIGO staging system for epithelial ovarian cancer, stage I is an admixture of 
different substages. The current study describes FIGO stage Ic ovarian cancer patients 
with a heterogeneity of different clinical presentations like capsule rupturing, ascites 
containing malignant cells, surface tumor and positive peritoneal fluid in relation to 
disease-free and overall survival.
Methods: Of the 448 patients randomized in the ACTION trial, 417 FIGO stage I 
ovarian cancer patients and 31 stage IIa patients were used for the recurrence-free and 
overall survival analysis.
Results: From the 417 FIGO stage I patients 155 (36%) were stage Ia, 37 stage Ib (9%) 
and 223 stage Ic (53%) patients. The 5-year overall survival was 82% for stage Ia, 86% 
for stage Ib and 81% for stage Ic, no statistical difference was found between these 
substages. Both disease-free and overall 5-year survival was not significant different for 
the Ic subcategories capsule rupture (71/80%), external surface tumor (76/88%) and 
positive ascites or malignant washings (67/78%). The time of capsule rupturing, before 
or during surgery, was not a prognostic factor.
Conclusions: This large series of early ovarian cancer patients shows no difference in 
prognosis between stage Ic patients compared to the other stages Ia and Ib patients. 
This study challenged the clinical significance of definition of stage Ic. Further clinical 
trials maybe define better prognostic factors in these ovarian cancer patients which 
could be incorporated in the FIGO staging system.
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INTRODUCTION
Epithelian ovarian cancer (EOC) accounts for approximately 25% of patients with disease 
confined to the ovaries (FIGO stage I). These patients are further subdivided according 
the last International Federation of Gynecology and Obstetrics FIGO classification in 
1985 depending whether one ovary (Ia) or both ovaries (Ib) are involved or if there 
was capsular rupture, surface tumor, ascites present that contains malignant cells or 
positive peritoneal washings (Ic) [1]. The importance of capsule rupturing was already 
incorporated in the FIGO staging system in 1971 [2]. The implications of substage 
in stage I are that it is generally supposed that the factors which assign patients to Ib 
or Ic carry a worse prognosis [3,4]. In several studies the 5-year survival for stage Ia 
patients is around 90-95% which decreases to 80-85% and 75-80% for stage Ib and Ic 
respectively [5-10]. However, many controversies still exist with regard to the relative 
importance of prognostic variables within stage I and in particular the independent 
significance of capsule rupture before or during surgery, surface tumor and positive 
peritoneal cytology. Some authors suggest that rupture of the tumor capsule [11,12] 
have a relevant impact on survival of early ovarian cancer patients and Ahmed et al. 
[10] identified the presence of ascites and surface tumor as independent prognostic 
factors. On the other hand, other studies did not confirm these findings [13,14]. 
The vast majority of the patients randomized in the EORTC ACTION trial 55904 
were FIGO stage Ic patients. To clarify the relevance of the different Ic substages we 
performed the current study. This analysis of patients randomized in the EORTC 
ACTION trial shows the results of the subgroups of FIGO stage Ic patients which consist 
of a heterogeneity of clinical presentations which maybe do have different impact in 
relation to recurrence rate and overall survival.
PATIENTS AND METHODS
All 448 patients were randomized in the European Organisation for Research and Treat-
ment of Cancer (EORTC) Adjuvant ChemoTherapy in Ovarian Neoplasm (ACTION, 
55904) trial which run between November 1990 and March 2000. Patients with FIGO 
stages Ia-Ib, grade 2 and 3, FIGO stages Ic-IIa, grade 1-3 and all grade stages Ic-IIa 
clear cell carcinoma were eligible for the study. Patients were randomized after surgical 
treatment between cisplatinum-based chemotherapy or no adjuvant chemotherapy 
(observation arm). Patients in the chemotherapy arm received at least four courses of 
platin-based chemotherapy. Patients in the observation arm were followed and treated 
according the institution policy by a clinically or histologically proven recurrence.
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For this analysis 417 patients FIGO stage I epithelial ovarian cancer patients (93%) 
and 31 stage IIa patients (7%) were used. From the 417 FIGO stage I patients 155 
(36%) were Ia, 37 stage Ib (9%) and 223 stage Ic (53%) patients. Information about 
clinical and histopathological features as well as for surgical staging were available for 
all patients. The mean follow-up at the time of the analysis was 5.6 years. For a detailed 
description and results of this trial we refer to a previous publication of Trimbos et al. 
[15]. Subgroup analysis was performed on the different FIGO stage Ic groups (n=223). 
Patients were classified according the International Federation of Gynecology and 
Obstetrics FIGO stage of 1985 [1].
Statistical analysis was performed using SPSS version 15.0 (SPSS inc., Chicago, IL). 
The Kaplan-Meier method was used for generating the disease-free and overall survival 
curves [16]. Comparison of survival distributions were made with the log-rank test with 
a significance defined as the P value < 0.05.
RESULTS
Table 1 shows the different FIGO stages of the 448 patients randomized in the EORTC 
ACION trial for both treatment arms. The FIGO stages were well balanced between 
the observation and the chemotherapy arm. The distribution of the FIGO stages was 
as follows: one-third of the patients (36%) were FIGO stage Ia (n=155), 9% stage 
Ib (n=37), 53% stage Ic (n=223) and 2% IIa (n=31). Further substages of the 223 Ic 
patients were 50 carcinomas on the ovarian surface (22%), 116 patients with Ic capsule 
rupture (52%) and 57 patients Ic with malignant washing or ascites (26%). From the 
Table 1. FIGO stages by treatment arm




Ia 76 (34%) 79 (35%)
Ib 18 (8%) 19 (8%)
Ic ovarian surface 28 (12%) 22 (10%)
Ic capsule rupture 52 (23%) 64 (29%)
Ic malignant washing/ascites 33 (15%) 24 (11%)
IIa 15 (7%) 16 (7%)
Unknown  2 (1%)  0
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116 patients with Ic capsule rupture, 84% of the rupturing occurred during operation, 
while 16% took place before surgery. The FIGO stage was missing in two patients. No 
significant difference was shown in the Ic stage for treatment arm, surgical staging 
category and differentiation grade as represented in Table 2. 
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Figure 1 shows the 5-year disease-free survival (DFS) of all 448 patients randomized 
in the ACTION trial with no significant difference for the different stages (P = 0.06). 
Figure 2 represents the overall survival curves of the three FIGO Ic substages. The 5-year 
overall survival for Ic substages, tumor on the surface, capsule rupturing and ascites 
or malignant cells containing peritoneal fluid were 76%, 71% and 67% respectively (P 
= 0.47). In the group of 223 FIGO stage Ic patients 53 recurrences occured, 11/50 
ovarian surface (22%), 26/116 capsule rupture (22%) and 16/57 malignant washing or 
ascites (28%). The 5-year disease-free survival ranged between 78 and 88% (P = 0.71) 
for the different Ic stages as shown in Figure 3. From the 223 patients in the FIGO stage 
Ic group, 40 (18%) died of the disease.
No significant difference was found in both disease-free and overall survival between 
the Ic capsule rupturing group before and during surgery. Although the 5-year disease-
free survival was better in the group with rupturing during operation (74%) compared 
to the group of rupturing before operation (64%), the overall 5-year survival showed 
an advantage in the group rupturing before surgery in comparison to rupturing during 
surgery, 85 versus 78% respectively. These differences were not statistically significant.
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Figure 2. Kaplan - Meier curves for overall survival in patients with early ovarian cancer in both treatment 
arms of the trial by FIGO Ic substages; Ic ovarian surface (n = 50), Ic capsule rupture (n = 116), Ic ascites/
malignant washing (n= 57). P = 0.47 using the log-rank test.
Figure 1. Kaplan - Meier curves for  disease-free survival in patients with early ovarian cancer in both treatment 
arms of the trial by FIGO stage; Ia (n = 155), Ib (n = 37), Ic ovarian surface (n = 50), Ic capsule rupture (n = 
116), Ic ascites/malignant washing (n= 57) and IIa (n = 31). P = 0.06 using the log-rank test.
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DISCUSSION
In the ACTION trial and the combined ACTION/ICON 1 analysis [11], FIGO stage was 
not a prognostic factor. FIGO stage Ic disease was not associated with a higher risk 
of recurrence or death compared to moderately and poorly differentiated FIGO stage 
Ia and Ib. In a recent meta-analysis of more than 1500 cases of early ovarian cancer 
patients, Vergote et al. found that stage Ic had a similar prognosis as stage Ib [17]. 
On the other hand, some other investigators showed a worse outcome in relation to 
tumor rupture [4] and capsule penetration [11,12], while Dembo et al. [14] found 
cyst rupture and capsular penetration not prognostic. This last study did not perform 
lymph node sampling and peritoneal biopsies in the absence of a palpable abnormality. 
Furthermore, most of these studies are retrospective analyses of small numbers of 
patients with sometimes unknown surgical staging procedure. Another reason for the 
inconsistency of the results may be the diverse treatment modalities. No difference in 
survival was observed between stage I subgroups ovarian carcinomas and stage IIa in 
a study of Sigurdsson et al. [6]. Our data confirm these findings, the 223 patients with 
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Figure 3. Kaplan - Meier curves for  disease-free survival in patients with early ovarian cancer in both treatment 
arms of the trial by FIGO Ic substages; Ic ovarian surface (n = 50), Ic capsule rupture (n = 116), Ic ascites/
malignant washing (n= 57). P = 0.71 using the log-rank test.
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Ic ovarian cancer showed a 5-year disease-free survival of 70% and a 5-year overall 
survival of 82% which was not worse than those patients with stage Ia and Ib. Although 
the statistical power of the current analysis was 0.63, the results of the ACTION trial 
describe the largest series of early ovarian cancer patients in a randomized trial until 
now. In our study also no survival difference was found between the different stage I 
patients, giving a 5-year overall survival of 83% for stage Ia (n=155), 88% for stage Ib 
(n=37), 82% for stage Ic (n=223) and 78% for stage IIa (n=31) patients. In a study done 
by Piver [18], the 5-year progression-free survival of 32 stage Ic grade 3 patients with 
invasive epithelial ovarian cancer was 90.5% and the 5-year survival was 93.3%, treated 
with cisplatin-based chemotherapy. In contrast to our findings, Brugghe et al. found 
FIGO substage the strongest prognosticator in 102 adequately staged Ia-Ic ovarian 
cancer patients who received no postoperative treatment [19].
In studies concerning stage Ic ovarian cancer patients a different prognostic value of 
capsule rupturing has been found. In a study of Krafft et al. [20] rupture and ascites 
drastically reduced the changes of survival in 60 patients with early ovarian cancer. 
Sainz de la Cuesta et al. [21] found a significant difference (P = 0.03) in the recurrence-
free survival of stage Ia (97 months) compared to stage Ic capsule rupture (78 months). 
The disease-free survival of the other Ic group (capsular invasion, positive ascites or 
washings) did not differ significantly from the Ic rupture group. The hazard ratios for 
overall survival associated with stage Ic-rupture and each potential confounder, except 
for bloating, exceeded 6.5. They concluded that intra-operative rupture of malignant 
epithelial ovarian neoplasms may worsen the prognosis of patients with stage I ovarian 
cancer. Prognostic factor analysis in 162 stage I high risk ovarian cancer patients 
performed by Tropé et al. showed that extracapsular growth and tumor rupture were 
significant independent factors with P values of 0.0005 and 0.04 respectively [22]. A 
multivariate analysis by Kodama et al. showed that capsular rupture caused by the 
surgeon did not affect the prognosis in stage I and II ovarian cancer [23]. Looking at 
our data the subcategories of Ic patients including capsule rupture (n=116), surface 
invasion (n=50) and ascites or malignant cells containing washings (n=57) showing 
5-year disease-free survival of 71%, 75% and 68% respectively (P = 0.71). The survival 
prognosis was not influenced by the different categories, giving 5-year overall survival 
percentages of 80% for Ic capsule rupturing, Ic surface of 89% and Ic positive ascites 
or washings of 79%. Villa et al. [9] reported a significant difference of 5-year survival 
between patients with tumor presence on the surface (88%) compared to intra-operative 
tumor rupture (72%).
The specific importance of rupture before or during operation is still unclear. Sevalda 
et al. reported no influence on survival rates for stage Ic capsule rupture during surgery 
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and therefore they considered that these patients do not belong to the subgroup Ic as 
suggested by the FIGO committee [5]. In a multivariate analysis of Vergote et al. both 
rupturing before as during surgery were independent predictors of disease-free survival, 
with rupturing before operation giving a higher change of recurrent disease [17]. The 
results of a study done by Mizuno et al. showed better survival curves for patients with 
rupturing during operation compared to the other Ic patients [24]. In contrast to these 
findings, Sjövall et al. found no difference in survival between those patients whose 
tumors had intact capsules and patients in whom rupture occurred during surgery, 
78% versus 85% respectively. The conclusion was drawn that manipulation during 
surgery which results in puncture or rupture does not have a negative influence on the 
outcome for the patients. On the other hand, a significant difference in survival was 
found between patients in whom rupture occured before surgery and those with intra-
operative rupture, 59% and 85%, respectively [25]. The results of our analysis with further 
subdivision of the Ic capsule rupture group into 19 patients where rupture occurred 
before surgery and 97 patients with rupturing during surgery shows a difference in both 
5-year recurrence-free survival (65% versus 74%) and overall survival (80% versus 89%) 
in favor of capsule rupturing during surgery but this difference reached no significancy.
In conclusion, in this large randomized trial in early ovarian cancer patients with 
a subset of more than 200 stage Ic patients no significant difference was found in 
recurrence rate and survival in the subsets of Ic patients, also no clear negative impact 
on survival and recurrence rate could be found for capsule rupturing before or during 
surgery. The current used FIGO staging system does not differentiate between low and 
high risk early ovarian cancer patients. Maybe other prognostic factors, like DNA ploidy 
and degree of differentation should be incorporated in a new staging system to divide 
patients with different prognosis.
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Appendix 1
Capsule rupturing in the International Federation of Gynecology and 
Obstetrics (FIGO) staging system
1964
Stage Ic  growth limited to one or both ovaries, ascites containing malignant cells
Capsule rupture not incorporated in staging system
1971
Stage Ia1/Ib1  growth limited to one ovary/both ovaries, capsule ruptured, no ascites
Stage Ia2/Ib2  growth limited to one ovary/both ovaries, capsule not ruptured, no ascites
Stage Ic1     growth limited to one or both ovaries, capsule ruptured, ascites containing 
malignant cells
Stage Ic2     growth limited to one or both ovaries, capsule not ruptured, ascites 
containing malignant cells
1975
Stage Ia1/Ib1 growth limited to one ovary/both ovaries, no tumor external surface, capsule 
intact, no ascites
Stage Ia2/Ib2 growth limited to one ovary/both ovaries, tumor external surface and/or 
capsule ruptured, no ascites
Stage Ic tumor either stage Ia or Ib and acites present or positive peritoneal washings
1985
Stage Ia growth limited to one ovary, no tumor external surface, capsule intact, no 
ascites
Stage Ib growth limited to both ovaries, no tumor external surface, capsule intact, no 
ascites
Stage Ic tumor either stage Ia or Ib, tumor on the external surface or capsule ruptured 
or ascites containing malignant cells or positive peritoneal washings
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ABSTRACT
A long-term follow-up analysis of the randomized clinical trial Adjuvant ChemoTherapy 
in Ovarian Neoplasm (ACTION) from the European Organisation for Research and 
Treatment of Cancer was undertaken to determine whether the orig inal results with a 
median follow-up of 5.5 years could be verified after longer follow-up with more events. 
In the ACTION trial, 448 patients with early ovarian cancer were randomly assigned, 
after surgery, to adjuvant chemotherapy or to observa tion (no further treatment). The 
original analysis found that adjuvant chemotherapy improved recurrence-free survival 
but not overall survival and found in a subgroup analysis that completeness of surgical 
staging was an independent prognostic factor, with better recurrence-free and overall 
survival among those with complete (optimal) surgical staging. After a median follow-
up of 10.1 years, we analyzed the more mature data from the ACTION trial and found 
support for most of the main conclusions of the original analysis, except that overall 
survival after optimal surgical staging was improved, even among patients who received 
adjuvant che motherapy (hazard ratio of death = 1.89, 95% confidence interval = 0.99 
to 3.60; overall two-sided log-rank test P = 0.05). More cancer-specific deaths were 
observed among non-optimally staged patients (40 [27%] of the 147 deaths in the 
observation arm and 11 [14%] of the 76 deaths in the adjuvant chemotherapy arm) 
than among optimally staged patients (seven [9%] of the 75 deaths in the observation 
arm and 11 [14%] of the 76 deaths in the adjuvant chemotherapy arm) (two-sided χ2 
test for heterogeneity, P = 0.06). Thus, completeness of surgical staging in patients with 
early ovarian cancer was found to be statistically significantly associated with better 
outcomes, and the benefit from adjuvant chemotherapy appeared to be restricted to 
patients with non-optimal surgical staging.
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INTRODUCTION
Results of the European randomized clin ical trial called Adjuvant ChemoTherapy in 
Ovarian Neoplasm (ACTION) conducted by the European Organisation for Research 
and Treatment of Cancer (EORTC) in patients with early epithelial ovarian cancer 
were published in 2003 [1], and its conclu sions have been discussed previously [2–6]. 
This trial included 448 patients who in the 2003 report [1] had a median follow-up 
of 5.5 years (range = 3 months to 9 years), a total of 100 recurrences registered, and 
78 deaths from ovarian cancer. Adjuvant chemotherapy that was administered after 
sur gical treatment statistically significantly improved recurrence-free survival but not 
overall survival [1]. Subgroup analysis on the effect of surgical staging indicated that the 
benefit of adjuvant chemotherapy appeared to be limited to patients who underwent 
non-optimal staging and so had a higher risk of undetected residual disease. In a 
subgroup analysis of patients with opti mal surgical staging, adjuvant chemotherapy 
was not associated with overall or recurrence-free survival.
In this study, we analyzed the mature data with a median follow-up of 10.1 years (95% 
confidence interval [CI] = 9.2 to 11.3 years) to test specifically whether the findings of 
the initial analysis would be robust over time. We repeated the initial analysis after a 
longer follow-up with more events and used cancer-specific survival to avoid the bias of 
intercurrent deaths (i.e., deaths from a cause other than ovarian cancer) because this 
risk increases with the duration of follow-up.
PATIENTS AND METHODS
Patients with epithelial ovarian cancer at stages Ia–Ib and grades 2–3 and all stages Ic 
and IIa and patients with clear cell cancer of the ovary (as defined by the International 
Federation of Gynecology and Obstetrics [FIGO]) at all stages I–IIa were eligble for the 
study. After surgery, patients were randomly assigned to adjuvant chemotherapy or to 
observation. The surgical staging procedure was divided into two groups: optimal and 
non-optimal staging. Optimal staging included removal of the affected ovary; removal 
of the uterus and contralat eral ovary (if a patient with a stage Ia tumor wanted to remain 
fertile, the uterus and contralateral ovary could be left in situ); careful inspection and 
palpation of all peritoneal surfaces and biopsy sampling of any suspicious areas, such 
as adhesions adjacent to the primary tumor; peritoneal washing for cytology analysis; 
infracolic omentectomy; blind peritoneal biopsy sam pling of the right hemidiaphragm, 
the right and left paracolic gutters, the pouch of Douglas, the bladder peritoneum 
and the pelvic side walls; and removal of para-aortic and pelvic lymph nodes. The 
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group of patients with non-optimal staging was further divided into the categories 
modi fied, minimal, and inadequate staging [1]. The ACTION trial was conducted 
between November 1, 1990, and January 23, 2000, in 40 centers from nine European 
countries (EORTC Gynaecological Cancer Group, trial registry number = 55904). The 
Institutional Review Board of each partici pating center had to approve the study, and 
informed consent of each patient was a prerequisite.
Cancer-specific survival was measured from the date of randomization to the date of 
death from ovarian cancer. Patients who were still alive or who had died of other causes 
were censored at their last known date alive. Recurrence-free survival was measured 
from the date of randomization to the first documented date of recurrence or death 
from any cause, whichever oc curred first. Both survival measures were estimated by 
the Kaplan–Meier method and compared by Cox proportional hazards regression 
(according to the intention-to-treat principle, after necessary assumptions were met) 
to determine statistically signifi cant covariates, such as FIGO stage, tumor grade, 
histological cell type, completeness of surgical staging, age, level of tumor marker 
CA125, and performance status. Differences in relative size of treatment effect between 
subgroups of staging perfor mance were tested by use of the χ2  test for interaction.
To analyze the mature data, follow-up was extended to May 23, 2008, increasing the 
median follow-up from 5.5 years in the original analysis to 10.1 years (95% CI = 9.2 to 
11.3 years). The follow-up duration was equal between the two treatment arms.
RESULTS
The number of events for the original analysis and this updated analysis are pre sented 
in Table 1. In a multivariable analysis that was adjusted for treatment, only the extent of 
surgical staging and tumor grade were statistically significantly associated with cancer-
specific survival (hazard ratio [HR] of death = 1.89, 95% CI = 1.23 to 2.91, for patients 
with non-optimal staging compared with those with optimal staging; P = 0.004; HR 
of death = 1.78, 95% CI = 1.24 to 2.56, for patients with poorly differ entiated tumors 
compared with those with well and moderate tumors; P = 0.002). In this analysis, well 
and moderately differen tiated tumors were combined because dif ferences between 
them were minimal.
Cancer-specific and recurrence-free survival for both the observation and the chemotherapy 
arms are given in Figure 1, A and B. After a 10-year follow-up, cancer-specific survival was 
similar between the two arms, but recurrence-free survival was statistically significantly 
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Table 1. Comparison of recurrences and deaths among the 448 patients (224 in the observation arm and 224 
in the adjuvant chemo therapy arm) from the original analysis (2003) and from the updated analysis of the 
mature data: the Adjuvant ChemoTherapy in Ovarian Neoplasm Trial*.
            Original analysis [1]            Analysis mature data
Events         Adjuvant  Observation       Adjuvant Observation
(deaths or recurrences) chemotherapy arm      arm chemotherapy arm       arm
Recurrences, No. (%)  40 (17.8) 60 (26.8) 61 (27.2) 87 (37.8)
Deaths, No.
(% of total deaths)
Total  33 (14.7) 45 (20.1) 52 (23.2) 67 (29.9)
From ovarian cancer  26 (78.8) 37 (82.2) 36 (69.2) 47 (70.1)
From other causes   5 (15.2)  8 (17.8) 12 (23.1) 19 (28.4)
From unknown causes   2 (6.0)  —  4 (7.7)  1 (1.5)
 
* Adjuvant chemotherapy had to consist of at least four courses of a platinum-based regimen after surgery but six 
courses were recommended.
higher in the chemotherapy arm (70%) than in the observation arm (62%) (difference = 
8%, 95% CI = 21.6% to 17.6%; HR for death = 0.64, 95% CI = 0.46 to 0.89, P = 0.007).
In both this analysis and the original analysis, patients were also separated into optimally 
and non-optimally staged groups. Among the optimally staged group, no differences 
were observed in 10-year cancer-specific survival and recurrence-free survival between 
the adjuvant chemo therapy and the observational arms (Figure 1, C and D).
In contrast, among the non-optimally staged group, statistically significantly better 10-
year cancer-specific survival was found among those in the adjuvant che motherapy arm 
(80%) than among those in the observation arm (69%) (difference = 11%, 95% CI = 
0% to 22%; HR for death = 0.58, 95% CI = 0.35 to 0.95, P = 0.029) (Figure 1, E). In 
addition, among the non -optimally staged group, statistically signifi cantly better 10-
year recurrence-free survival was found among those in the che motherapy arm (65%) 
than among those in the observation arm (56%) (difference = 9%, 95% CI = 22.8% to 
20.8%; HR for death = 0.60, 95% CI = 0.41 to 0.87, P = 0.007) (Figure 1, F).
Among patients in the observation arm after a median follow-up of 10.1 years, op timally 
staged patients had statistically sig nificantly better rates for cancer-specific survival and 
recurrence-free survival than non-optimally staged patients (Table 2). Among patients 
in the chemotherapy arm after a median follow-up of 10.1 years, the rates for cancer-
specific survival and recurrence-free survival were similar in optimally staged patients 
and non-optimally staged patients (Table 2).
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CONTEXT AND CAVEATS
Prior knowledge
In the randomized clinical trial Adjuvant ChemoTherapy in Ovarian Neoplasm, 448 
patients with early ovarian cancer were randomly assigned, after surgery, to adju vant 
chemotherapy or to observation. After a median follow-up of 5.5 years, adjuvant 
chemotherapy was associated with improved recurrence-free survival but not overall 
survival. In a subgroup analysis, better recurrence-free and over all survival were observed 
among those with non-optimal surgical staging than those with optimal staging.
Study design
Long-term analysis of data from this trial after a median of 10.1 years of follow-up.
Contribution
The long-term analysis supported most conclusions from the original analysis, except 
that overall survival after optimal surgical staging was improved, even among patients 
who received adjuvant chemo therapy. More cancer-specific deaths were observed 
among non-optimally staged patients than among optimally staged patients.
Implications
Completeness of surgical staging among patients with early ovarian cancer was 
statistically significantly associated with better outcomes, and the benefit from adjuvant 
chemotherapy was restricted to patients with non-optimal surgical staging.
Table 2. The 10-year cancer-specific survival and recurrence-free survival rates by the extent of surgical staging: 
the Adjuvant ChemoTherapy in Ovarian Neoplasm Trial*.
              % survival (95% CI)
________________________________
Survival type and arm
 With optimal With non-optimal       
HR (95%)   P†      staging       staging
Cancer-specific survival
 Observation 89 (79 to 95) 69 (60 to 77) 3.28 (1.47 to 7.33) 0.002
 Chemotherapy 85 (73 to 92) 80 (71 to 86) 1.27 (0.62 to 2.58) 0.52
Recurrence-free survival
 Observation 72 (59 to 81) 56 (47 to 64) 1.91 (1.17 to 3.11) 0.009
 Chemotherapy 78 (66 to 86) 65 (56 to 73) 1.64 (0.91 to 2.93) 0.09
*CI = Confidence Interval; HR = hazard ratio of death or recurrence.
† The statistical test was the two-sided log-rank test.
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Limitations
The trial was not designed to compare dif ferent surgical staging procedures. Patients 
could not be prospectively stratified by surgical staging category. The study had a 
limited sample size. Quality of life was not studied.
Because the differentiation grade of early ovarian cancer is a strong prognostic factor for 
survival, the optimally staged 156 patients in the ACTION trial with a poorly differentiated 
(grade 3) tumor (78 in the observation arm and 78 in the adjuvant chemotherapy arm) 
were analyzed sepa rately. After a median follow-up of 10.1 years, we found no differences 
between the observation and the chemotherapy arms in stage, age, performance status, 
histological cell type, or cancer-specific survival (Figure 1, G, and Table 3). This finding 
did not change when the optimally staged patients with a grade 3 tumor were analyzed 
sepa rately. However, when non-optimally staged patients with a grade 3 tumor were 
ana lyzed, cancer-specific survival was better in the adjuvant chemotherapy arm than in 
the observation arm (HR of death = 0.40, 95% CI = 0.19 to 0.81, P = 0.009) (Table 3).
The long-term results of the ACTION trial strongly substantiate the results of the original 
analysis [1], with only one excep tion. After 10.1 years of follow-up, the multivariable 
analysis found no association between cancer-specific survival and histo logical cell type. 
Both staging adequacy and differentiation grade remained highly sta tistically significant 
prognostic factors. A well or moderately differentiated tumor, compared with a poorly 
differentiated tumor, was associated with increased cancer-specific survival (HR of 
death = 1.78, 95% CI = 1.24 to 2.56).
Table 3. Recurrence-free survival (RFS) and cancer-specific survival (CSS) after 10 years of follow-up among 
the 156 patients with poorly differentiated (grade 3) tumors: the Adjuvant ChemoTherapy in Ovarian 
Neoplasm Trial*
              % survival (95% CI)
_________________________________
  Observation Chemotherapy
Survival type and group      arm        arm     HR (95% CI) P†
Optimal staging
 RFS 64 (40 to 80) 49 (27 to 68) 1.25 (0.53 to 2.95) 0.61
 CSS 85 (60 to 95) 69 (43 to 85) 2.58 (0.66 to 9.99) 0.15
Non-optimal staging
 RFS 52 (38 to 65) 55 (39 to 69) 0.58 (0.33 to 1.02) 0.05
 CSS 56 (41 to 68) 77 (61 to 87) 0.40 (0.19 to 0.81) 0.009
* CI = Confidence Interval; HR = hazard ratio of death or recurrence.
† The statistical test was the two-sided log-rank test.
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For the analysis of data with a median follow-up of 10.1 years, we deliberately choose 
to report cancer-specific survival instead of overall survival because results for overall 
survival were the same as in the original analysis, except that in the chemo therapy arm, 
statistically significantly better overall survival was found in the group with optimal 
surgical staging than in the group with non-optimal staging. Thus, the mature data 
support a beneficial effect of optimal surgical staging for patients with early ovarian 
cancer, even among those receiving adjuvant chemotherapy (HR of death = 1.89, 95% 
CI = 0.99 to 3.60; overall two-sided log-rank test P = 0.05).
For the entire cohort studied in the ACTION trial after a median follow-up of 10.1 years, 
cancer-specific survival was not associated with adjuvant chemotherapy. However, 
adjuvant chemotherapy was associated with statistically significantly improved 
recurrence-free survival (HR of death = 0.64, 95% CI = 0.46 to 0.89). Among optimally 
staged patients, recurrence-free survival was similar for both the obser vation arm (72%) 
and the adjuvant chemotherapy arm (73%), as was cancer-specific survival (89% and 
86%, respec tively). Thus, the conclusions of the original report of the ACTION trial 
appear to be robust and consistent during 10.1 years of follow-up. Among the group 
with poorly differentiated tumors, it is of interest that survival between optimally and 
non-optimally staged patients followed the same pattern. Among all patients with a 
grade 3 tumor, the recurrence-free survival and cancer-specific survival were lower than 
those of the entire cohort; this observation is consistent with the dismal prognosis of 
poorly differentiated tumors [7]. However, findings from the analysis with a median 
follow-up of 10.1 years indicate that ad ministration of adjuvant chemotherapy after 
optimal surgical staging in this group is not associated with improved survival, perhaps 
because poorly differentiated early ovarian carcinomas have a tendency to metastasize 
earlier than those that are well differentiated [8]. Optimal surgical staging might detect 
this early spread so that patients with occult stage III disease can be identified and 
separated from the group of really early ovarian carcinomas.
Survival analyses (Figure 1, C–F) indi cated that the completeness of staging (optimal 
vs non-optimal) in the ACTION trial defined two subgroups in which adju vant 
chemotherapy has different effects: no benefit in the optimally staged group and a 
statistically significant benefit in the non-optimally staged group. The heterogeneity 
in cancer-specific survival was also observed between the treatment effects and the 
staging groups, as shown in forest plots (Figure 2) and with a χ2 test for interaction 
(cancer-specific deaths among the non-optimally staged patients = 40 [27%] of the 
147 deaths in the observation arm and 11 [14%] of the 76 deaths in the adjuvant che-
motherapy arm; and among optimally staged patients, cancer-specific deaths = seven 
[9%] of the 75 deaths in the observa tion arm and 11 [14%] of the 76 deaths in the 
adjuvant chemotherapy arm; two-sided χ2 test for heterogeneity, P = 0.06).
 Surgical staging and treatment: long-term analysis 127
8
DISCUSSION
This study has several limitations. The ACTION trial was not specifically designed to 
compare different surgical staging pro cedures, and patients could not be prospec-
tively stratified according to the various surgical staging categories. Retrospective 
stratification, however, showed a well-balanced distribution of the various staging 
categories between the two treatment arms (data not shown), and no differences in the 
distribution of other risk factors, such as tumor grade and histological cell type between 
optimally and non-optimally staged patients. Furthermore, the study suffered from a 
limited sample size. At the time of the study design, no realistic power calcula tion could 
be made, so the sample size was arbitrarily set to 1000 or more patients. Because of 
the slow accrual of patients, this number was not met, despite the fact that this is the 
largest randomized trial in this disease with an observation arm and com paring the 
extent of surgical staging. Finally, the ACTION trial did not study quality of life. At the 
time that the study was planned, quality-of-life analyses were not yet considered an 
important element of clinical trials.
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Figure 2. Forest plots of the interaction between the two staging categories (optimal and 
nonoptimal) vs treatment effect (adjuvant chemotherapy better vs observation better) for 
cancer-specific survival. Solid squares = hazard ratios (HRs) for cancer-specific survival 
(with the area of the square being proportional to the variance of the estimated effect); length 
of the horizontal line through the square = 95% confidence interval (CI); open diamond = 
HR (middle of the diamond); horizontal points of the diamond = 95% CI for the combined 
data. CSS = cancer-specific survival; EORTC = European Organization of Research and 
Treatment of Cancer; O - E = number of events observed minus number of events expected 
under the null hypothesis; SD = standard deviation; Var. = variance of 1 divided by the 
logarithm of the HR. Linear trends and heterogeneity of the HRs to detect differences in 
relative size of treatment effect were assessed by a χ
2 
test for interaction. All statistical tests 
were two-sided. 
Test for treatment interaction: CSS
Figure 2. Forest plots of the interaction between the two staging categories (optimal and non-optimal) vs 
treatment effect (adjuvant chemo therapy better vs observation better) for cancer-specific survival. Solid 
squares = hazard ratios (HRs) for cancer-specific survival (with the area of the square being proportional 
to the variance of the estimated effect); length of the horizontal line through the square = 95% confi dence 
interval (CI); open diamond = HR (middle of the diamond); horizontal points of the dia mond = 95% CI 
for the combined data. CSS = cancer-specific survival; EORTC = European Organisation of Research and 
Treatment of Cancer; O - E = number of events observed minus number of events expected under the null 
hypothesis; SD = standard deviation; Var. = variance of 1 divided by the logarithm of the HR. Linear trends 
and heterogeneity of the HRs to detect differences in relative size of treat ment effect were assessed by a χ2 test 
for inter action. All statistical tests were two-sided.
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The design of our study permits no clear-cut guidelines for the treatment of all categories 
of patients with early ovarian carcinoma. It seems clear, however, that non-optimally 
staged patients should be restaged or be given adjuvant chemotherapy if restaging is not 
feasible. Although some people will argue that a P value for hetero geneity of 0.06 in a 
subgroup analysis is still insufficient evidence to withhold adjuvant chemotherapy from 
all patients with early ovarian cancer who received optimal sur gical staging, others will 
take the view that, in the largest randomized trial on this issue after a median follow-up 
of 10.1 years, the consistent lack of an association between cancer-specific or recurrence-
free survival and adjuvant chemotherapy among optimally staged patients is con vincing 
evidence to restrict administration of chemotherapy even for patients with grade 3 
tumors [6]. The latter point of view is supported by the observation that 20% of long-
term survivors of ovarian cancer will develop a secondary primary tumor as a result of 
their treatment with platinum-based chemotherapy [9]. In addition, a randomized study 
design that included de liberately assigning half of the patients to improper surgery would 
be unethical because of the proven beneficial prognostic effect of adequate surgery.
In conclusion, the long-term analysis of the ACTION trial data 1) substantiated the 
original findings of the ACTION trial that the completeness of surgical staging in early 
ovarian cancer is an independent prognostic factor for recurrence-free and overall sur-
vival, even when adjuvant chemotherapy is given after surgery and 2) substantiated the 
original conclusion of the ACTION trial that “ the benefit of adjuvant chemo therapy 
appears to be limited to patients with non-optimal staging, i.e., patients with more risk 
of unappreciated residual disease” [1].
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ADJUVANT CHEMOTHERAPY IN EARLY OVARIAN CANCER
The Adjuvant ChemoTherapy in Ovarian Neoplasm (ACTION) trial is one of the largest 
randomized trials in early ovarian cancer patients together with the ICON 1 trial [1,2].
The results of the ACTION trial show that adjuvant platin-based chemotherapy delays 
disease recurrence in patients with early-stage ovarian cancer, of whom 297 of the 448 
patients (66%) had undergone non-optimal surgical staging. No statistically difference 
was found for overall survival in the entire group of patients randomized in the ACTION 
trial, but was found when combining the results of the ACTION and ICON 1 trials. 
If we look at the patients in the observation arm who were optimally staged, both 
disease-free survival and overall survival were statistically better compared to the non-
optimally staged patients in the same arm. The relatively poor prognosis of the non-
optimally staged patients could be corrected by administrating adjuvant platinum-
based chemotherapy. These results suggest that adjuvant chemotherapy in early-stage 
ovarian carcinoma may work predominantly by affecting microscopic metastases that 
remain unnoticed during the staging laparotomy. This hypothesis is supported by the 
finding that chemotherapy improved both overall and recurrence-free survival in the 
non-optimally staged patients and not in the optimally staged patients. The finding 
that adjuvant chemotherapy is effective in non-optimally staged patients might also 
explain the results of the ICON1 trial [2] and the combined ICON1/ACTION analysis 
[3], in which the majority of patients were most probably not optimally staged. 
Another finding in this study was the difference in the percentage of patients successfully 
treated for tumor recurrence between the optimally and non-optimally staged group. 
The optimally staged patients showed a higher salvage rate in the observation arm than 
in the chemotherapy arm, 75% versus 46%, respectively. In the non-optimally staged 
patients however the salvage rate was similar in both arms, 70% and 64%. In a study 
of the Italian Gruppo Interregionale Collaborative Oncology Group GICOG the same 
difference of effectiveness of chemotherapy was found in patients were a complete 
surgical staging was performed [4].
A second long-term follow-up analysis of the ACTION trial was performed after a 
median follow-up of 10.1 years, which substantiated the main conclusions that the 
benefit of adjuvant chemotherapy is most clear in the non-optimally staged patients 
and that the completeness of surgical staging is an independent prognosticator for 
both disease-free and overall survival [5].
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SURGICAL STAGING
In the present study the completeness of surgical staging was found to be an independent 
prognostic factor by multivariate analysis. This is not a surprising finding because the 
completeness of surgical staging influences the likelihood of remaining residual disease. 
Optimal staging reduces the chances of metastases in the lymph nodes, omentum and 
peritoneum and incomplete surgical staging increases the possibility of hidden occult 
cancer in the peritoneal cavity. The prognostic value of the extent of surgical staging in 
early ovarian cancer has been found by others as well [6,7].
Although the particular staging steps were precisely mentioned in the protocol of the 
ACTION trial and strongly advised to carry out, only one-third of the patients entered in 
the study were optimally staged. In order to reduce this very low number we have tried 
to figure out what the reasons are why so many patients are not completely staged. 
One of the reasons may be that a substantial part of the patients with early ovarian 
cancer are diagnosed during a surgical procedure for acute abdominal pain or an 
ovarian mass and operated by a general gynecologist who does not have the surgical 
skills to perform an optimal surgical staging and has a lack of knowledge about the 
mechanisms of tumor spread in the abdominal cavity. 
To perform a complete surgical staging surgical skills are needed and sufficient 
knowledge of the routes of metastases of ovarian cancer. In our study we have tried to 
differentiate between a lack of surgical skills for procedures involving morbidity on one 
hand or lack of sufficient knowledge of risk sites for ovarian cancer spread to carry out 
easy procedures without appreciable morbidity risk on the other. Pelvic and para-aortic 
lymph node sampling, procedures which carry a potential morbidity, were omitted in 
78% and 52% respectively in the non-optimally staged group. In a previous Dutch study 
similar results were found [8], in 70% of the study population no lymph node sampling 
was done and also another study showed the same figure [9]. As we examine in the 
present study the easy procedures like taking blind biopsies of the paracolic gutters and 
from the pelvic side wall we found that it was omitted in 39% of the patients. Peritoneal 
washings were not done in 11% of the cases.
The role of  lymph node sampling or lymphadenectomy on the prognosis in early ovarian 
cancer remains controversial. In a study of Baiocchi et al. [10] lymph node status was 
the most valuable prognostic factor in patients with disease limited to the ovary. A 
randomized study by Maggioni et al. [11] compared systemic pelvic and para-aortic 
lymphadenectomy to random sampling of lymph nodes in macroscopic early ovarian 
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cancer. In the systemic lymphadenectomy group the incidence of positive nodes was 
significantly higher: 22% versus 9% in the random sampling group, but the recurrence 
rate ( 22% and 30% respectively) nor the survival were significantly different [11]. In our 
study we found a significant difference in both disease-free and overall survival but our 
study compared lymph node sampling versus no sampling in the group patients who 
received no adjuvant treatment whereas in the trial of Maggioni an unknown percentage 
received postoperative chemotherapy. The limitation of our study is the relatively small 
number of patients in a subgroup analysis but on the other hand results are derived 
from one of the largest series in early ovarian cancer patients.
So both factors like insufficient surgical skills and knowledge are probably responsible 
for the staging problem in early ovarian cancer. To do something about these 
shortcomings, a better organization of the referral policy of patients with a suspicion of 
early ovarian cancer to a center with gynecologic oncologists is necessary.
Another finding of the ACTION trial was the number of patients enrolled by the different 
institutes and the percentage of complete staging. The hospitals which entered less than 
5 patients performed in 20.5% of the patients an optimal staging while this percentage 
increase to nearly 37% if more than 10 patients were enrolled in the trial. This volume 
issue plays an important role in oncology. In a population based study of 2450 ovarian 
cancer patients by Ioka et al. [12], patients treated in very low volume hospitals were 
seen to have a 60% higher change of death compared to patients receiving care in high 
volume hospitals (P < 0.01). 
So if we allow too many institutes which randomize a low number of patients in a trial 
the chance of inadequate adherence to the study protocol increases. For early ovarian 
cancer trials this means a non-optimal performance of the required surgical staging 
steps.
To improve the quality of surgical staging in early ovarian cancer patients Verleye et al. 
[13] proposed quality indicators for the staging laparotomy in ovarian cancer grossly 
confined to the pelvis. Kommoss et al. [14] found that the introduction of a quality 
insurance and management program for treatment of early ovarian cancer patients 
have led to a major improvement of patient care.
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SUBSTAGES AND HISTOLOGIC T YPES
In both the ACTION and the combined ACTION/ICON 1 analyses FIGO (sub)stage 
was not a significant prognostic factor. The 5-year survival curves for all stages were as 
follows; 83% for stage Ia (n=155), 88% for stage Ib (n=37), 82% for stage Ic (n=223) and 
78% for stage IIa (n=31) patients. In a study of Sigurdsson et al. [15] also no difference 
in survival was observed between stage I subgroups ovarian carcinomas and stage IIa 
as we found in our analyses. In a meta analysis by Vergote et al. FIGO stage Ic and 
FIGO stage Ib patients showed to have similar prognosis [16]. Contrary to our findings 
Brugghe et al. found FIGO substage the strongest prognosticator in 102 adequately 
staged Ia-Ic ovarian cancer patients who received no postoperative treatment [17].
If we look in detail to the Ic substage we found no significant difference in recurrence 
and death rate compared to patients with moderately and poorly differentiated FIGO 
stage Ia and Ib.
Another issue of Ic patients is the subdivision of capsule rupture, extracapsular growth 
and positive washings or malignant cells containing ascites. Some authors associated 
these factors with a worsening prognosis [18-22] while others did not find a difference 
in prognosis in the different Ic patients [23,24]. A flaw of these studies is the relatively 
small number of patients, sometimes unknown surgical staging procedure and different 
treatment modalities. If we look at our three Ic substage groups, Ic capsule rupturing 
(n=116), surface invasion (n=50) and Ic ascites or malignant cells containing ascites 
(n=57), 5-year disease-free survival was 71%, 75% and 68% respectively with a P-value 
of  0.71. Also overall survival was not significantly different between the subgroups.
The specific importance of rupture before or during operation is still unclear. Sevalda 
et al. reported no influence on survival rates for Ic capsule rupture during surgery and 
therefore they considered that these patients do not belong to the subgroup of Ic as 
suggested by the FIGO committee [25]. In a multivariate analysis of Vergote et al. 
both rupturing during and before surgery were independent predictors of disease-free 
survival, with rupturing before operation giving a higher change of recurrent disease 
[16].
The results of our study, with further subdivision of the Ic capsule rupture into 19 
patients with rupture before surgery and 97 patients where rupture took place during 
surgery, show a difference in both 5-year recurrence-free survival (65% compared to 
74%) and overall survival (80% versus 89%) in favor of capsule rupturing during surgery. 
However this difference did not reach significance.
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So in conclusion, we did not find a significant difference in either disease-free survival 
or overall survival of the 223 different substages Ic ovarian cancer patients and also 
no significant negative impact of capsule rupturing during or before surgery. Maybe 
for further classification of patients with early ovarian cancer other prognostic factors 
like DNA ploidy or differentation grade should be incorporated in a new FIGO staging 
system to select patients with adverse prognosis.
Clear cell carcinomas are generally supposed to worsen the prognosis in ovarian cancer 
patients and do have special clinical features which have been widely studied. Nulliparity 
of more than 50% have been reported in many series [26-28] as well as concurrent 
endometriosis in 8-55% of the patients with clear cell carcinoma compared to 5% of the 
serous ovarian cancer patients [29-31].
We performed a study in 63 clear cell carcinoma (CCC) patients and 156 serous 
adenocarcinoma (SAC) patients. In our study group 3.2% of the CCC patients had 
pelvic extension while 9.6% of the SAC patients had FIGO stage IIa. In the literature no 
studies reported a primary pelvic variant of clear cell tumors, while mucinous and serous 
primary peritoneal cancers are described. Okhawa et al. suggested another reason why 
clear cell tumors stay localized. They found that clear cell tumors remain attached to 
the mesothelial layer while serous cancers rapidly invade into this cell layer [32].
Furthermore, we found a high percentage of Ic capsule rupture among the CCC patients 
(44.4%) compared to 18.6% of the SAC patients. A possible explanation for this 
biologic phenomenon might be a larger tumor size or more endometriosis associated 
with adhesions of CCC as described in many series [26,32-35], and therefore more 
frequent capsule rupture before or during surgery.
Looking at the recurrence rate in our series we found a similar number of recurrences in 
the CCC group compared to the SAC group, 25.4% versus 25.6%, respectively. Different 
percentages of relapse rates are described in the literature, ranging from very low, 6% 
[36] to 37% [34]. Some studies suggest that the high relapse rate may be related to 
chemoresistance. In support of this concept, clear cell carcinoma cell lines were found 
to exhibit resistance to cisplatin in cell culture [37]. Itamochi et al. [38] suggested 
that the resistance could be explained by a lower cell proliferation in CCC cell lines 
compared to SAC cell lines which they found in a conducted study.
In our study we found that the disease-free survival (DFS) showed an advantage in the 
observation arm in favour of the CCC patients, while in the chemotherapy arm the DFS 
was better in the SAC patients. Both differences were statistically not significant but 
could partly be explained by the chemoresistance in clear cell tumors.
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The 5-year overall survival in the CCC group was 63% compared to 72% in the SAC 
group. Zanetta et al. [7] analysed 351 patients with stage I ovarian cancer and did not 
find a significant difference in DFS and OS comparing clear cell tumors versus other 
histologic types. Many other studies also did not find a survival difference between CCC 
and SAC patients [16,30,39,40] while Jennison et al. [28] showed a significant better 
5-year survival of 87% in 11 SAC patients compared to 50% in 11 CCC patients.
We conclude that clear cell carcinomas do have special clinical features but they show 
a similar prognosis compared to serous early ovarian cancer patients. In further trials 
of early ovarian cancer the possible chemoresistance of clear cell carcinomas should be 
examined in detail.
CONCLUSIONS AND FUTURE CONCEPTS
From this large randomized trial in early ovarian cancer patients we have learned that the 
patients entered in the trial who were non-optimally staged benefit most from adjuvant 
chemotherapy and that the patients who were optimally staged have less effect of an 
adjuvant chemotherapy. The completeness of surgical staging was a prognostic factor 
and to influence the low figure of adequate and complete surgical staging, gynecologic 
oncologists must be part of the operation team or the patients have to be referred and 
restaged if possible and otherwise receive chemotherapy.
Furthermore we found that clear cell carcinomas in early ovarian cancer are not such bad 
actors as generally supposed. The different FIGO Ic substages were not of prognostic 
value in our study and neither was capsule rupturing before or during surgery in the 
subgroups of stage I-II patients with moderately or poorly differentiated tumors.
This trial also does have its limitations; it was not primarily designed for subgroup 
analyses, included only the moderately or high risk group of stage I patients and 
although it is one of the largest series in early ovarian cancer it has still a limited sample 
size.
In future trials we have to stress that an optimal surgical staging has to be performed 
and we do need to examine new prognostic factors to help us selecting patients who 
will be at high risk for recurrence. Also quality of life issues must be part of the study 
design.
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In chapter 1 a general description is given about the epidemiology, surgical staging, 
treat ment modalities and prognostic factors of early-stage ovarian carcinoma.
In chapter 2 the results are described of the ACTION trial comprising 448 patients 
with early-stage ovarian carcinoma (from 40 centers in nine European countries), who 
were randomized between platinum-based chemotherapy (n=224) or observation 
(n=224) following surgery. After a median follow-up of 5.5 years, the difference in 
overall survival between the two trial arms was not statistically significant. Recurrence-
free survival, however, was significantly improved in the adjuvant chemotherapy arm 
(HR=0.63, 95% CI=0.43 to 0.92; P = 0.02). Approximately one-third of patients 
(n=151) had been optimally staged and two-thirds (n=297) had not. Among patients 
in the observation arm, optimal staging was associated with a statically improvement in 
overall and disease-free survival. No such association was observed in the chemotherapy 
arm. We concluded that adjuvant chemotherapy was associated with statistically 
significantly improved recurrence-free survival in patients with early-stage ovarian 
cancer. The benefit of adjuvant chemotherapy appeared to be limited to patients with 
non-optimal staging, i.e., patients with more risk of unappreciated residual disease.
Chapter 3 is a review paper of different randomized conducted trials until now in 
early ovarian carcinoma and a literature study. The implication of these data is that a 
complete surgical staging is of utmost importance and should be pursued. In cases of 
non-optimal staging and contra-indications for restaging, adjuvant chemotherapy is 
indicated to deal with unnoticed residual tumor deposits that exist in approximately 
25% of the cases.
In chapter 4 we compared the survival of patients with clear cell carcinoma (CCC) 
to patients with serous adenocarcinoma (SAC) in the ACTION trial. Furthermore, a 
literature search was done to clarify the clinical and histopathological features of clear 
cell tumors of the ovary. Sixty-three patients (14.1%) were compared with 156 patients 
(34.8%) with serous tumors. No significant difference was found in overall survival 
between patients with CCC and patients with SAC in both trial arms together. In the 
observation arm, the 5-year disease-free survival was 71% in the CCC group versus 61% 
in the SAC group, whereas in the chemotherapy arm, the 5-year disease-free survival 
was higher in the SAC group compared to the CCC group. Both differences were not 
statistically significant. The present study showed no worse prognosis in patients with 
CCC as compared to patients with serous carcinoma in early ovarian cancer.
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Chapter 5 describes the problem of inadequately surgical staging. Incomplete surgical 
staging during the initial operation of patients with presumed early-stage ovarian 
carcinoma has been reported between 32% and 72% in different studies. Knowledge of 
the reasons for the wide spread inadequacy of staging early ovarian cancer is lacking. 
The EORTC-ACTION trial is one of the largest randomized clinical trials in early ovarian 
cancer so far. Detailed information about the staging procedure was available for every 
patient.
In this trial strict criteria for the surgical staging were advised, however, optimal, 
complete staging was performed in only one-third of  the patients. Staging characteristics 
of the 295 incomplete staged patients were analysed and factors that could explain 
the omission of a comprehensive staging were studied. Sampling of para-aortic lymph 
nodes was not performed in 78% of the incomplete staged patients, while 52% of these 
patients had no pelvic lymphnode sampling. Omission of the staging steps varies from 
3% (infracolic omentectomy) to 55% (biopsy right hemidiaphragm). Even staging 
steps without morbidity like peritoneal washing (11%) and taking of blind biopsies 
from the paracolic gutter or side wall (39%) were omitted. The percentage completely 
staged patients was 20.5% for institutes who randomized less than 5 patients and this 
percentage increased to 37% when more than 10 patients were included in the trial.
Even in a randomized trial where complete surgical staging was advised in the study 
protocol the majority of the patients (67%) were incompletely staged. Multicenter trials 
which recruited patients from different low volume institutes run the risk of inadequate 
adherence to the study protocol.
In chapter 6 we studied the value of lymph node sampling and taking of blind biopsies 
in the surgical staging of early ovarian cancer. Patients with early-stage ovarian cancer 
are often understaged. The staging steps that are most frequently omitted include the 
taking of blind peritoneal biopsies and lymph node sampling or lymph node dissection. 
The incidence of positive nodes in apparently early ovarian cancer is approximately 15% 
for stage I and 36% for stage II as described in several studies.
Despite the importance of these staging steps it seems difficult to carry them out in 
daily practice. The reasons of not performing these steps are partly explained by a lack 
of technical skills and partly because a lack of knowledge of early ovarian cancer spread.
This study describes the effect of lymph node sampling and taking of blind biopsies 
as part of the surgical staging for early ovarian cancer on disease-free and overall 
survival. For the current study 224 patients randomized in the observation arm of the 
ACTION trial were included. Of these 224 patients, 75 patients were optimally staged 
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(group A), 46 patients in whom all staging steps were performed except para-aortic or 
pelvic lymph node dissection (group B) and 14 patients where no blind biopsies were 
taken but who fulfilled all other staging steps (group C). A significant difference was 
found (P = 0.03) in the 5-year disease-free survival between group A (optimally staged) 
and group B (no lymphnode sampling) of 79% versus 61%. Furthermore a significant 
difference was shown in the 5-year survival between group A (89%) and group B (71%). 
Also a significant difference was found in the both the 5-year disease-free survival (P = 
0.02) and the 5-year overall survival (P = 0.003) between group A (optimally staged) 
and group C (no blind biopsies) resulting in a 5-year disease-free survival of 79% versus 
64% respectively and a 5-year survival of 89% (group A) and 65% (group C).
Although this study is limited by a relatively small number of patients, it demonstrates 
the importance of taking blind biopsies and performing a lymph node sampling for the 
prognosis of patients with early-stage ovarian cancer.
The prognosis of the different FIGO Ic patients is described in chapter 7. Patients with 
diverse FIGO stage Ic presentations like capsule rupturing, ascites containing malignant 
cells or positive peritoneal fluid and surface tumor showed no significant different 
disease-free and 5-year overall survival. The recurrence-free and overall 5-year survival 
was as follows for the different Ic subcategories: capsule rupturing (73%/80%), external 
surface tumor (76%/88%) and positive ascites or malignant washings (70%/78%). Also 
the time of capsule rupturing, before or during surgery, was not a prognostic factor in 
the current study
The long-term results of the ACTION trial are shown in chapter 8. After a median 
follow-up of 10.1 years most of the main conclusions of the original analysis remain 
the same. This means improved recurrence-free survival but not overall survival by 
adjuvant chemotherapy and the completeness of surgical staging as an independent 
prognostic factor, with better recurrence-free and overall survival among patients who 
were optimally staged. Furthermore, we found in the long-term analysis that overall 
survival after optimal surgical staging was improved, even among patients who received 
adjuvant chemotherapy. Thus, completeness of surgical staging in patients with 
early ovarian cancer was proven to be statistically significantly associated with better 
outcomes, and the benefit from adjuvant chemotherapy appeared to be restricted to 
patients with non-optimal surgical staging.
Finally, in chapter 9 we described the conclusions of the ACTION trial and future concepts 
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In hoofdstuk 1 wordt een algemene beschrijving gegeven van de epidemiologie, 
chirurgische stagering, behandelingsmodaliteiten en prognostische factoren van het 
vroeg stadium ovariumcarcinoom.
In hoofdstuk 2 worden de resultaten beschreven van de ACTION studie waarbij 448 
patiënten met een vroeg stadium ovariumcarcinoom (uit 40 instituten in negen 
Europese landen) werden gerandomiseerd tussen adjuvante platinum bevattende 
chemotherapie (n=224) of observatie (n=224) na chirurgie. Na een mediane follow-
up van 5.5 jaar was het verschil in overleving tussen de twee studie-armen statistisch 
niet significant. De recidief-vrije overleving was echter statistisch significant beter in de 
adjuvante chemotherapie groep (HR=0.63, 95% CI=0.43 tot 0.92; P = 0.02). Ongeveer 
eenderde van de patiënten (n=151) was optimaal gestageerd en tweederde (n=297) 
niet. Bij de patiënten in de observatie-arm was optimale stagering geassocieerd met een 
significant betere totale en ziektevrije overleving. Deze associatie werd niet gevonden in 
de chemotherapie-arm. We concludeerden dat adjuvante chemotherapie geassocieerd 
was met een statistische verbetering van de recidief-vrije overleving bij patiënten met een 
vroeg stadium ovariumcarcinoom. Het nut van adjuvante chemotherapie lijkt zich te 
beperken tot patiënten die niet optimaal gestageerd zijn, dat wil zeggen, patiënten die 
meer risico hebben op onopgemerkte residuale ziekte.
Hoofdstuk 3 is een overzichtsartikel over de verschillende gerandomiseerde studies tot 
op heden bij het vroege ovariumcarcinoom en een literatuurstudie. De implicatie van 
deze data is dat complete chirurgische stagering van het allergrootste belang is en zou 
moeten worden uitgevoerd. In het geval van een niet-optimale stagering of indien er 
contra-indicaties bestaan voor restageren, is adjuvante chemotherapie geïndiceerd 
om onopgemerkte residuale tumor deposities, die voorkomen in ongeveer 25% van de 
gevallen, te bestrijden.
In hoofdstuk 4 vergeleken we de overleving van de clear cell carcinoom patiënten (CCC) 
met de sereuze adenocarcinoom patiënten (SAC) in de ACTION studie. Verder werd 
een literatuurstudie verricht naar de klinische en histopathologische karakteristieken 
van het clear cell carcinoom van het ovarium. Er werden 63 CCC patiënten (14.1%) 
vergeleken met 156 SAC patiënten (34.8%). Er werd geen verschil gevonden in de totale 
overleving tussen de patiënten met CCC en met SAC in beide studie-armen tezamen. In 
de observatie-arm was de 5-jaars ziektevrije overleving 71% in de CCC groep versus 61% 
in de SAC groep terwijl in de chemotherapie-arm de 5-jaars ziektevrije overleving hoger 
was in de SAC groep vergeleken met de CCC groep (78% en 60%). Deze verschillen 
waren statistisch niet significant. De huidige studie toonde geen slechtere prognose 
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voor patiënten met een clear cell carcinoom in vergelijking tot patiënten met een sereus 
carcinoom bij het vroege ovariumcarcinoom.
Hoofdstuk 5 beschrijft het probeem van inadequate chirurgische stagering. Incomplete 
chirurgische stagering tijdens de initiële operatie van patiënten met een ogenschijnlijk 
vroeg stadium ovariumcarcinoom is in verschillende studies beschreven variërend tussen 
de 32% en 72%. Kennis omtrent de redenen voor de wijdverspreide inadequate stagering 
van het vroege ovariumcarcinoom ontbreekt. De EORTC-ACTION studie is één van de 
grootste gerandomiseerde klinische studies naar het vroege ovariumcarcinoom tot op 
heden. Gedetailleerde informatie over de stageringsprocedure was beschikbaar voor 
iedere patiënt.
In deze studie werden stricte criteria voor de chirurgische stagering geadviseerd, echter 
optimale, complete stagering werd in slechts eenderde van de patiënten uitgevoerd. 
Stageringskarakteristieken van de 295 incompleet gestageerde patiënten werden 
geanalyseerd en factoren die het niet verrichten van een complete stagering mogelijk 
kunnen verklaren werden bestudeerd. Sampling van de para-aortale lymfklieren werd 
bij 78% van de incompleet gestageerde patiënten niet verricht, terwijl 52% van deze 
patiënten geen pelviene lymfkliersampling onderging. Omissie van de stagerings-stappen 
varieerde van 3% (infracolische omentectomie) tot 55% (biopt rechter diafragma 
koepel). Zelfs stagerings-stappen zonder morbiditeit zoals het afnemen van spoelvocht 
(11%) en het nemen van biopten van de para-colische groeven en bekkenwand (39%) 
werden overgeslagen. Instituten die minder dan 5 patiënten randomiseerden hadden 
een percentage van 20.5% compleet gestageerde patiënten terwijl dit percentage 
toenam naar 37% indien meer dan 10 patiënten werden geïncludeerd in de studie. 
Zelfs in een gerandomiseerde studie waar complete chirurgische stagering werd 
geadviseerd in het studieprotocol werd de meerderheid van de patiënten (67%) 
incompleet gestageerd. Multicenter studies die patiënten recruteren van verschillende 
laag volume instituten lopen het risico van inadequate adherentie aan het studie 
protocol.
In hoofdstuk 6 wordt bestudeerd wat de waarde is van het verrichten van een 
lymfkliersampling en het nemen van blinde biopten in de chirurgische stagering van 
het vroege ovariumcarcinoom. Patiënten met een vroeg stadium ovariumcarcinoom 
worden vaak chirurgisch ondergestageerd. De stagerings-stappen die het meest frequent 
worden nagelaten zijn het nemen van blinde peritoneale biopten en het verrichten van 
een lymfkliersampling danwel lymfklierdissectie. De incidentie van positieve lymfklieren 
in een ogenschijnlijk vroeg stadium ovariumcarcinoom is ongeveer 15% in stadium I 
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en 36% in stadium II zoals beschreven in diverse studies. Ondanks het nut van deze 
stagerings-stappen levert de uitvoering ervan in de dagelijkse praktijk regelmatig 
problemen op. De redenen van het niet uitvoeren ervan zijn deels te verklaren door 
een gebrek aan technische vaardigheden en deels door een gebrek aan kennis van de 
verspreidingsroute van het vroege ovariumcarcinoom.
Deze studie beschrijft het effect van lymfkliersampling en het nemen van blinde biopten 
als onderdeel van de chirurgische stagering bij het vroege ovariumcarcinoom op de 
ziektevrije en totale overleving. Voor deze studie zijn de 224 patiënten die gerandomiseerd 
zijn in de observatie-arm van de ACTION studie geïncludeerd. Van deze 224 patiënten 
waren er 75 patiënten optimaal gestageerd (groep A), bij 46 patiënten waren alle 
stagerings-stappen uitgevoerd behoudens de para-aortale of iliacale lymfkliersampling 
(groep B) en bij 14 patiënten waren er geen blinde biopten genomen maar verder wel de 
overige stappen (groep C). Er werd een significant verschil gevonden (P waarde 0.03) in 
de 5-jaars ziektevrije overleving tussen groep A (optimaal gestageerd) en groep B (geen 
lymfkliersampling) van 79% versus 61%. Verder werd er ook een significant verschil 
gezien in de 5-jaars overleving tussen groep A (89%) en groep B (71%). Een significant 
verschil werd eveneens gevonden voor zowel de 5-jaars ziektevrije overleving (P waarde 
0.02) als de 5-jaars overleving (P waarde 0.003) tussen groep A (optimaal gestageerd) 
en groep C (geen blinde biopten) resulterend in een 5-jaars ziektevrije periode van 79% 
versus 64% respectievelijk en een 5-jaars overleving van 89% (groep A) en 65% (groep 
C). Ondanks de beperking van deze studie met relatief kleine aantallen patiënten per 
groep demonstreert het wel de noodzaak van het nemen van blinde peritoneale biopten 
en het verrichten van een lymfkliersampling voor de prognose van patiënten met een 
vroeg stadium ovariumcarcinoom.
De prognose van de verschillende FIGO Ic patiënten wordt beschreven in hoofdstuk 7. 
Patiënten met diverse FIGO Ic presentaties zoals kapselrupturering, maligne cellen 
bevattende ascites of positief peritoneaal spoelvocht tonen geen significant verschillende 
5-jaars ziektevrije en totale overleving. De 5-jaars recidief-vrije en totale overleving 
waren als volgt voor de verschillende Ic subcategorieën: kapselrupturering (70%/78%), 
tumor aan het buitenoppervlak (76%/88%) en positieve ascites of maligne spoelvocht 
(70%/78%). Ook het tijdstip van kapselrupturering, voor of tijdens de operatie, bleek 
geen prognostische factor in de huidige studie.
De lange-termijn resultaten van de ACTION studie worden getoond in hoofdstuk 8. Na 
een mediane follow-up van 10.1 jaar bleven de meeste van de belangrijkste conclusies 
van de originele analyse hetzelfde. Dit betekent, verbeterde recidief-vrije overleving, maar 
geen verbeterde totale overleving bij adjuvante chemotherapie en de compleetheid van 
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de chirurgische stagering als onafhankelijke prognostische factor, met betere recidief-
vrije en totale overleving bij patiënten die optimaal waren gestageerd. Verder vonden we 
bij de lange-termijn analyse dat de totale overleving na optimale chirurgische stagering 
verbeterd was, zelfs bij de patiënten die adjuvante chemotherapie hadden gekregen. Dus, 
compleetheid van chirurgische stagering bij patiënten met een vroeg ovariumcarcinoom 
is statistisch bewezen significant geassocieerd met een betere uitkomst, en het nut van 
adjuvante chemotherapie lijkt beperkt tot patiënten die niet optimaal gestageerd zijn.
Tenslotte beschrijven we in hoofdstuk 9 de conclusies van de ACTION studie en toekomstige 
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